State and municipal people’s governments, provincial committees, offices, departments and bureaus:

"Yunnan Province" 14 th Five-Year Plan "for the Innovation and Development of Biomedical Industry has been agreed by the provincial people’s government and is hereby issued to you, please implement it carefully.

General Office of Yunnan Provincial People’s Government

March 17, 2022

(This piece is publicly released)

In order to accelerate the innovation and development of the biomedical industry, this plan is formulated according to the 14th Five-Year Plan for National Economic and Social Development in Yunnan Province and the Outline of Long-term Objectives for the Year 2035, combined with the reality of our province.

I. Development Status and Situation

(A) Development effectiveness

During the "Thirteenth Five-Year Plan" period, the provincial party committee and the provincial government conscientiously implemented the spirit of the important speech of the Supreme Leader General Secretary on his inspection of Yunnan, and on the basis of continuously building eight key industries and world-class "three cards", put forward the strategic deployment of focusing on cultivating five trillion-level pillar industries and eight billion-level advantageous industries and building a modern industrial system. Biomedical industry, as a strategic emerging industry with a focus of 100 billion yuan in our province, has steadily expanded its scale, significantly enhanced its innovation ability, increasingly optimized its policy environment, and continuously improved its economic benefits. Its operating income increased from 124.109 billion yuan in 2015 to 252.145 billion yuan in 2020, with an average annual growth rate of 15.23%, and its added value increased from 36.587 billion yuan in 2015 to 73.14 billion yuan in 2020. The average annual growth rate reached 14.86%, the business income and added value doubled, and a research and production system of biotechnological drugs focusing on vaccines was gradually formed, and a whole industrial chain development system of natural drugs (ethnic Chinese medicines) featuring proprietary Chinese medicines, Chinese herbal pieces, extracts and health products was established.

In 2020, the province’s Chinese herbal medicine planting (breeding) industry will realize an operating income of 51.611 billion yuan; The biomedical manufacturing industry realized an operating income of 59.592 billion yuan; The biomedical commerce and trade industry realized an operating income of 140.942 billion yuan. There are 163 pharmaceutical manufacturing enterprises above designated size (including 1 enterprise with operating income exceeding 10 billion yuan and 5 enterprises with 1-10 billion yuan). There are 48 varieties with sales income exceeding 100 million yuan (including 5 varieties exceeding 1 billion yuan and 4 varieties with 500-1 billion yuan). Up to now, there are 9 biomedical enterprises listed on the main board and growth enterprise market in the province.

1. The biotechnology pharmaceutical industry has made breakthrough development.

In 2020, the province’s biological products manufacturing industry above designated size represented by vaccines achieved an operating income of 5.357 billion yuan, accounting for 15.6% of the operating income of pharmaceutical manufacturing industry above designated size. There are 13 vaccine varieties on the market, and the operating income of vaccine enterprises has increased from 800 million yuan in 2009 to 4.8 billion yuan in 2020, and the biotechnology drug industry has made breakthrough progress. The inactivated enterovirus 71 vaccine independently developed by the Institute of Medical Biology, Chinese Academy of Medical Sciences was launched in December 2015, and the annual operating income of a single variety was nearly 2 billion yuan. The 23-valent pneumococcal polysaccharide vaccine developed by watson biological was launched in July 2017, with an operating income of 688 million yuan in 2020; The first trivalent pneumococcal polysaccharide conjugate vaccine in China and the second trivalent pneumococcal polysaccharide conjugate vaccine in the world went on the market in April 2020, with an operating income of 1.658 billion yuan in the first year, and the market prospect is considerable. Some traditional pharmaceutical companies and scientific research units have accelerated the layout and development of biotechnological drugs. Suparutide injection, a long-acting hypoglycemic drug developed by Kunyao Group, has obtained clinical approval, and Sino Pharmaceutical has carried out research on new drugs of humanized CD22 antibody immunotoxin 1.1.

2 Chinese medicine (ethnic medicine) industry scale

In recent years, the traditional Chinese medicine (ethnic medicine) industry in our province has become the main force to promote the development of biomedical industry from small to large and from weak to strong. 60 "Hometowns of Yunyao" and 103 "Pharmaceutical Parks" have become the new force to improve the quality and brand of Chinese herbal medicines. In 2020, the main business income of planting (breeding) and product processing of Chinese herbal medicines in the province will exceed 100 billion yuan, among which the processing and manufacturing of Chinese herbal medicines above designated size, such as proprietary Chinese medicines, Chinese herbal pieces, extracts and health products, will achieve an operating income of about 48 billion yuan, accounting for over 80% of the main business income of biomedical industries above designated size. The planting area of Chinese herbal medicines exceeds 9 million mu, the planting area of 15 varieties of Chinese herbal medicines, such as Panax notoginseng, Paris polyphylla, Dendrobium, Amomum villosum and Radix Aucklandiae, exceeds 100,000 mu, and the standardized planting base of Chinese herbal medicines covers an area of 1.46 million mu, including 22,000 mu of green certification base and 126,000 mu of organic certification base. Sanqi, Erigeron breviscapus industry has formed a whole industrial chain layout of planting, processing, R&D and production, which has played a very prominent role in demonstrating the development of traditional Chinese medicine industry in the province. Panax notoginseng industry has achieved standardization and standardized planting, and developed relatively complete back-end products such as decoction pieces, preparations and health products, which has become a big variety second only to ginseng. The planting area of the whole province is about 400,000 mu, and the agricultural output value is about 6 billion yuan. A number of Chinese patent medicines and injections such as Panax notoginseng decoction pieces, Xuesaitong soft capsules, Xuesaitong for injection (freeze-dried powder injection), Xuesaitong tablets, Xuesaitong capsules, Panax notoginseng saponins and Xuesaitong injection, etc.

3. The chemical medicine industry has developed steadily.

In 2020, the chemical preparation manufacturing industry and the chemical raw material medicine manufacturing industry above designated size will realize an operating income of 3.52 billion yuan, accounting for 10.2% of the pharmaceutical manufacturing industry above designated size. Initially gathered a number of chemical pharmaceutical enterprises such as Jida Pharmaceutical, Baker Norton, Haobang Pharmaceutical, Sino Pharmaceutical, Longhai Pharmaceutical and Guiyan Pharmaceutical; Longjin Pharmaceutical, Haobang Pharmaceutical and Plant Pharmaceutical cooperated with Indian generic drug companies to actively introduce Indian generic drug varieties to Yunnan; Nine varieties, including amoxicillin capsules, chlorphenamine maleate tablets and ambroxol hydrochloride injection, passed the consistency evaluation of chemical generic drugs.

4. Remarkable achievements have been made in biomedical science and technology innovation.

Driven by scientific and technological innovation, the biomedical industry has gradually embarked on a high-quality development track. Sabin inactivated poliomyelitis vaccine, EV71 inactivated enterovirus vaccine, 13-valent pneumococcal polysaccharide conjugate vaccine and other fist products have been listed one after another, and some varieties are undergoing WHO pre-certification; Covid-19 inactivated pneumonia vaccine, F gene mumps live attenuated vaccine, nine-valent human papillomavirus (HPV) vaccine, rotavirus inactivated vaccine and tetravalent meningococcal polysaccharide conjugate vaccine are in the clinical research stage, which has provided strong support for the rapid development of the vaccine industry during the Tenth Five-Year Plan. Ten innovative drugs, such as KPCXM18, a natural medicine for treating ischemic stroke, Duanjin Jiedu Capsule, a 6-class Chinese medicine, Suparutide injection, and a 1.1-class new drug of bungarus multicinctus venom, were approved by the national drug clinical approval. Winona series products, with authentic Yunnan medicinal materials as the main raw materials, have developed into an important functional skin care brand in China. "Key Technology Creation and Industrial Application of Comprehensive Development of Panax notoginseng" won the second prize of National Science and Technology Progress Award, "Key Technology and Application of Standardization and Industrial Development of Panax notoginseng" won the first prize of Yunnan Science and Technology Progress Award, and three standards of Panax notoginseng, seeds and seedlings and Gastrodia elata passed the international quality standard certification. Panax notoginseng saponins and breviscapine have passed GRAS (generally considered safe) certification recognized by FDA, and entered the catalogue of American botanical medicine raw materials;Tongshu capsule and Xuesaitong soft capsule were approved by FDA to carry out phase II clinical research.

Around the great demand of the development of biomedical industry, a number of R&D service platforms have been built, such as Yunnan Biovaccine Technology Innovation Center, Yunnan Drug Non-clinical Safety Evaluation Research Center, Yunnan Natural Drug Activity Screening and Evaluation Center, Yunnan Stem Cell and Regenerative Medicine Research Center, Yunnan Flower Aromatic Health Products R&D Center, and Yunnan Chinese Medicine Seed Breeding R&D Center. By the end of the 13th Five-Year Plan, there were 47 provincial key laboratories in the biomedical field, 20 engineering technology research centers, 19 engineering research centers, 10 clinical medical research centers and 4 academicians of the two academies in the province, and 12 provincial science and technology leaders were trained, 54 provincial high-level talents were introduced, 4 high-level innovation and entrepreneurship teams were introduced, 553 provincial young and middle-aged academic and technological leaders and 553 provincial innovative talents were trained.

5. Bio-pharmaceutical industry has achieved initial results by attracting big and strong players.

Yunnan Baiyao Group introduced social capital to complete the mixed reform, and the development of the group entered the fast lane; China Resources Sanjiu acquired Kunming Shenghuo Pharmaceutical, and the company’s operating income increased significantly; Guizhou Bailing invested in Yunnan plant pharmaceutical industry, focusing on characteristic products, optimizing product structure, and implementing large-variety brand strategy. The scale of the enterprise has maintained rapid growth for many years. Well-known enterprises inside and outside the province, such as Sinopharm Group, Shanghai Pharmaceutical Group, Guangzhou Pharmaceutical Group, Tasly Pharmaceutical, Kangenbei Pharmaceutical, Shenwei Pharmaceutical, New Green Pharmaceutical, Beijing Tongying, Fangsheng Pharmaceutical, Jilin Xingshen, Hong Kong Juzhang and Shenzhen Botton, have landed in Yunnan and actively participated in the healthy development of the biomedical industry.

(B) Advantages and shortcomings

1. Location advantage

Yunnan has outstanding geographical advantages. It is adjacent to Guizhou and Guangxi in the east, Sichuan in the north, Tibet in the northwest, and Myanmar, Laos and Vietnam in the west and south. It is an important channel connecting South Asia, Southeast Asia and the Indian Ocean region, and an important intersection of the "Belt and Road" construction and the national development strategy of the Yangtze River Economic Belt. The biomedical industry has a huge potential market, which can be built on the basis of vaccines and traditional Chinese medicine (ethnic medicine)

2. Resource advantages

Yunnan has obvious three-dimensional climate characteristics, many types, beautiful mountains and rivers, pleasant climate and outstanding biodiversity characteristics. It is known as the "plant kingdom", "animal kingdom", "microbial kingdom", "hometown of medicinal materials" and "treasure house of biological genes", and is the province with the richest biological resources, natural medicines and ethnic medicine resources in China. According to the statistics of the third national survey of traditional Chinese medicine resources, there are 6,559 kinds of traditional Chinese medicine resources in the province, accounting for 51.4% of the total number of kinds in the country, more than 2,000 kinds of ethnic medicine resources and more than 10,000 folk prescriptions.

3. Advantages of industrial base

Notoginseng Radix, Rhizoma Paridis Yunnanensis, Erigeron breviscapus, Dendrobium candidum, Fructus Amomi, Rhizoma Gastrodiae, Poria Yunensis, Radix Angelicae Sinensis, Radix Aucklandiae, Radix Gentianae Yunnanensis and other "Top Ten Yunyao" brand medicinal materials have excellent quality and are widely recognized in the industry. It has built a domestic raw material base for high-quality natural medicines and health products. The large varieties of Yi medicine represented by Yunnan Baiyao, the unique ethnic medicines such as Dai and Naxi, and the unique ethnic medical technologies such as Dai medicine, which are in the same strain as the traditional medical systems of neighboring countries, provide rich ethnic medical resources for the innovation, inheritance and development of traditional Chinese medicine and the opening up of markets for South Asian and Southeast Asian countries. Gu Fangzhou, known as the "father of polio vaccine in China", engaged in the research of live attenuated polio vaccine in Yunnan, established the method of isolation and finalization of polio virus, formulated the trial production and safety standards of live polio vaccine, and formulated the "Rules for the manufacture and verification of live polio vaccine", which guided the production and identification of billions of vaccines in China and laid a solid foundation for the rapid development of vaccine industry in our province.

4. Shortcomings of rapid industrial development

First, the industry is small in scale and weak in competitiveness. The overall scale of Yunnan’s biomedical industry is small. Among the top 500 main business incomes of the national pharmaceutical industry, there are only 10 in Yunnan. The overall competitiveness of the biomedical industry, which is dominated by traditional Chinese medicine, is weak, especially affected by the national medical reform policies such as the catalogue of auxiliary drugs of traditional Chinese medicine, the catalogue of medical insurance, and the consistency evaluation of traditional Chinese medicine injections. The scale of biomedical manufacturing industry has declined slightly for two consecutive years.

Second, the industrial structure is not excellent and the industrial chain is incomplete. The development of standardized planting (breeding) bases of Chinese herbal medicines lags behind, the phenomenon of small varieties of Chinese herbal medicines is prominent, the research foundation is uneven, and the competitiveness of products is generally weak; Vaccines are the main biotechnological drugs, but the pipelines of antibody drugs, biological similar drugs, cell products, blood products and other products are not rich, and the upstream and downstream supporting industries are basically blank; Small amount of chemicals, lack of original research drugs and high-end generic drugs; The development level of medical devices and veterinary drugs is low.

Third, the core competitiveness of enterprises is weak, and the degree of specialization of the park is low. There are few well-known enterprises and leading enterprises, leading enterprises are not aware of advanced layout and innovative R&D activities, and the industry is not leading enough; Insufficient investment in research and development, lack of influential and innovative varieties, and weak core competitiveness; The level of professional development of biomedical industrial park is not high, the supporting system is not perfect, and the public R&D and service capabilities are weak.

Fourth, innovation ability is not strong, and high-level talents are lacking. The research and development system of new drug creation is imperfect, the resources are scattered, and the technical level is not high, which does not match the needs of the industrial chain; Lack of forward-looking scientific research ability for common technologies, key technologies and cutting-edge technologies needed for rapid industrial development; There are few innovative products in other industries except vaccines; The linkage between enterprises and scientific research institutions is not close, and the contradiction between supply and demand in the transformation of scientific and technological achievements is prominent; Lack of high-level R&D innovation centers and insufficient public R&D service platforms such as drug safety evaluation (GLP), drug clinical evaluation (GCP) and contract R&D institutions (CRO); There is a serious shortage of high-level innovative talents, management talents and teams.

Fifth, brand building is not enough, and market development ability is weak. Enterprises are weak in coping with industrial policies such as medical reform, drug review and approval, and drug production supervision, and weak in market cultivation and brand building of their own products; There is a lack of systematic publicity highlighting the advantages and characteristics, insufficient excavation of superior Chinese herbal medicine varieties, time-honored traditional Chinese medicine and ethnic medicine culture, and weak brand building and market promotion of "Yunyao".

(3) Opportunities and challenges

1. Health needs are increasing.

With the increase of sub-health population and the acceleration of population aging, people’s demand for health products has increased rapidly; The demand for health consumption has changed from medical treatment to disease prevention, health care and health promotion; The national new medical reform plan puts the prevention and control of diseases in the first place, and pays more attention to "preventing diseases before they occur". Traditional Chinese medicine (ethnic medicine) will be promising.

2. Building a domestic and international dual cycle will bring new opportunities for industrial development.

The COVID-19 epidemic has had a great impact on the global industrial chain and supply chain. It is an inevitable requirement to maintain a stable and healthy economic development by adjusting the economic development path, opening up the international circulation, smoothing the domestic circulation, coordinating development and security, enhancing the autonomy, sustainability and resilience of economic development. Seize the development opportunities brought by the Regional Comprehensive Economic Partnership Agreement (RCEP), make full use of Yunnan’s geographical advantages in connecting South Asia, Southeast Asia and the Indian Ocean region, and exchange the traditional medicine with neighboring countries, realize the smooth connection with the biomedical industry in South Asia and Southeast Asia, and accelerate the construction of a new international and domestic dual-cycle development pattern.

3. The epidemic situation in COVID-19 affected the development pattern of pharmaceutical industry.

After the outbreak of COVID-19, COVID-19’s vaccine research and development and production have become the focus of international competition in the field of biotechnology drugs, which puts forward new requirements for the corresponding research and development technology system, experimental evaluation, manufacturing capacity level and organizational management efficiency. With the development of modern biotechnology such as genetic engineering, cell engineering, tissue engineering, biosynthesis, bioinformatics and precision medicine, biotechnological drugs such as vaccines and antibody drugs have become the main direction of the transformation and upgrading of the biomedical industry. The competitive advantages of prescription and medicine represented by "three drugs and three parties" are prominent, and the modern innovative Chinese medicine with clear mechanism of action and definite clinical effect has obvious competitiveness. The demand for medical materials represented by ventilators, testing reagents, medical masks and protective clothing has surged, which has promoted the development of the medical device industry.

4. Competition in domestic pharmaceutical industry is becoming increasingly fierce.

All provinces (autonomous regions and municipalities) take biomedicine as a priority industry, and Beijing, Shanghai, Jiangsu, Guangdong and other provinces (municipalities) have been at the forefront of the country by virtue of their own geographical, policy, talent and technical advantages; Shandong, Sichuan, Hubei, Jiangxi and other provinces have also accelerated the pace of industrial development, and the competition between regions has become increasingly fierce. The reorganization of enterprises in the industry is frequent, and super-large enterprises are constantly emerging. The development trend of agglomeration is obvious, full of opportunities and challenges.

5. The medical reform policy forces the pharmaceutical industry to develop with high quality.

The research and development, production and sales of pharmaceutical products are highly dependent on policy factors, and the industrial development is deeply influenced by policy regulation. The continuous adjustment of various policies, such as drug supervision, the catalogue of traditional Chinese medicine auxiliary drugs and the new medical insurance catalogue, has prompted pharmaceutical enterprises to increase investment in research and development, take a higher quality development path, change from extensive development to refined development mode, and change products from imitation to original innovation. At the same time, information technology represented by mobile medical care, cloud computing, big data and Internet of Things has begun to penetrate into all aspects of the biomedical industry.

6. Competition for innovative drugs has intensified.

At present, the research and development of major innovative drugs are still led by well-known multinational companies, and the competition for technology, talents and funds in the biomedical industry is extremely fierce. Large pharmaceutical companies focus on developing innovative drugs for clinical value in the fields of biotechnology drugs and chemical drugs, while expanding new indications of existing products and expanding upstream and downstream business chains. Pharmaceutical companies with obvious competitive advantages in core products, diversified products and outstanding R&D capabilities will have stronger competitiveness and anti-risk ability. The global vaccine industry presents an oligopoly pattern, with the top 10 companies accounting for 95.7% of the total vaccine market share, and the four vaccine giants GSK (GlaxoSmithKline), Merck, Sanofi and Pfizer accounting for about 80% of the total market share. In the future, the global vaccine market has great growth potential and will grow rapidly with a compound annual growth rate of 10%. The rapid development of frontier technologies such as gene therapy and cell therapy is expected to form major innovative drugs and new supporting technologies. The patents of the top 10 original drugs in global sales, such as Hummel, Merlot and Avastin, are about to expire, and generic drugs and bio-similar drugs are expected to usher in new opportunities. From the national situation, the major achievements of new drug research and development are mainly concentrated in Beijing, Shanghai, Jiangsu and other places, and innovative enterprises led by new drug research and development, such as Hengrui Pharma and Wuxi PharmaTech, have a strong development momentum.

Second, the development ideas, principles and objectives

(A) development ideas

Guided by the Supreme Leader’s Socialism with Chinese characteristics Thought in the New Era, we will fully implement the spirit of the 19th National Congress of the Communist Party of China and the previous plenary sessions of the 19th National Congress, thoroughly study and implement the spirit of the important speech of the Supreme Leader’s General Secretary on his visit to Yunnan, conscientiously implement the decision-making arrangements of the provincial party committee and government, grasp the new development stage, implement the new development concept, serve and integrate into the new development pattern, adhere to the problem-oriented, goal-oriented and result-oriented, take innovation as the core, quality as the foundation, and take enterprises as the main body. Market-oriented, focusing on the three key areas of biotechnological drugs, modern Chinese medicine and health products, we will focus on attracting investment accurately, strengthening the main body of enterprises, enhancing innovation ability, building industrial clusters, promoting industrial development with engineering measures, building domestic first-class R&D and production bases of biological vaccines and modern Chinese medicine, domestic top-quality raw materials bases of natural drugs and health products, and biomedical trade bases facing South Asia and Southeast Asia, forming an industrial cluster with important influence in the country, and realizing the high-quality development of Yunnan biomedical industry.

(2) Basic principles

1. Innovation-driven, quality-improved development

Around the industrial chain, deploy innovation chain, build a batch of high-level public service platforms and professional R&D platforms, break through a batch of technologies, reserve a batch of achievements, develop a batch of products and transform a batch of achievements, and promote the high-quality development of Yunnan biomedical industry.

2. Based on advantages and outstanding features

Based on the advantages of Yunnan’s location, ecology, environment, resources and nationality, we will highlight the characteristics of biological vaccines, authentic medicinal materials, ethnic medicine, classic and famous prescriptions, proven prescriptions and cell technology, strengthen product quality and standards, and accelerate industrial transformation and upgrading.

3. Government guidance and market dominance

Innovate institutional mechanisms, rationally allocate resources, break through policy bottlenecks, cultivate and expand market players, release enterprise vitality and market potential, and build a sound market system and policy system.

4. Open cooperation and push forward together.

Improve the soft and hard environment, expand the domestic and foreign markets, and support local enterprises to become bigger and stronger; Introduce well-known enterprises and scientific research achievements to expand the increment; Attracting scientific research institutes from outside the province to develop in Yunnan, jointly cultivating talents, focusing on R&D and innovation, and forming a strong synergy to promote industrial development.

(III) Overall objectives

By 2025, the operating income of the biomedical industry will achieve the goal of "ensuring four guarantees and competing for five", that is, it will reach 400 billion yuan and strive to reach 500 billion yuan, with an average annual growth rate of more than 10%. Among them, the biomedical manufacturing industry will achieve an operating income of more than 150 billion yuan, with an average annual growth rate of more than 20%. The added value of biomedical industry reached 120 billion yuan, with an average annual growth rate of more than 10%. Strive for the biological vaccine industry to achieve the number and value of batch issuance. Facing 2035, we will focus on key markets, increase promotion, actively tap the domestic market, vigorously explore the South Asia and Southeast Asia markets, further enhance the influence and market share of the brand "Yunyao", and build Yunnan into a biomedical R&D innovation and product production and trade center with distinctive characteristics of serving the whole country and radiating South Asia and Southeast Asia, and build an industrial cluster with important influence in the country.

-do it on a large scale. By 2025, we will cultivate more than one enterprise (group) with operating income exceeding 50 billion yuan, more than five enterprises (groups) exceeding 10 billion yuan, more than five enterprises (groups) exceeding 5 billion yuan, more than 20 enterprises (groups) exceeding 1 billion yuan and more than 70 enterprises exceeding 100 million yuan.

-strengthen varieties. By 2025, more than 10 varieties with sales income exceeding 1 billion yuan and more than 60 varieties with sales income exceeding 100 million yuan will be cultivated.

-do an excellent structure. By 2025, the leading development of biotechnological drugs will be realized, modern Chinese medicine (ethnic medicine) will be upgraded and developed, dual-use products for medicine and food will develop by leaps and bounds, and chemical drugs and medical devices will make breakthroughs.

-fill in the short board. We will build and upgrade a number of public R&D and service platforms around biotechnology drugs, modern Chinese medicine and chemical drugs, break through a number of key core technologies, and develop a number of competitive and innovative products.

Third, key tasks

Around the biomedical industry chain, deploy innovation chain, promote the organic integration of industry chain and policy chain, innovation chain, capital chain, supply chain, talent chain and value chain, focus on key core technologies, fill the shortcomings of the platform and increase high-quality varieties. Strengthen leading enterprises and enhance manufacturing capacity. Optimize the industrial layout, strengthen the construction of the park, and form industrial agglomeration. Enhance the brand of "Yunyao", revitalize the stock, introduce increments, expand the total amount, and realize the high-quality development of the biomedical industry.

(1) Strengthen varieties and accelerate the transformation and upgrading of biomedical manufacturing.

Give priority to the development of biological vaccines, modern Chinese medicines (ethnic medicines), Chinese herbal pieces and chemical medicines, vigorously develop biotechnological medicines such as antibody medicines, gene technology, cell therapy and blood products, as well as health products, detection and diagnosis reagents, medium and high-end medical devices, strengthen the research and innovation of biotechnological medicines, modern Chinese medicines, natural medicines, generic medicines, new preparations and health care products, and support the internationalization of vaccines, modern Chinese medicines and medical devices. Focusing on increasing investment in scientific and technological innovation, building a number of well-known enterprises and brand products, introducing large enterprises and groups, encouraging enterprises to acquire and merge, and promoting international development, we will promote digital and intelligent manufacturing and accelerate the transformation and upgrading of biomedical manufacturing.

1. Key development areas

(1) Biotechnology drugs focusing on vaccines

The biotechnology pharmaceutical industry focusing on vaccines is the fastest-growing field in the biomedical industry in our province, and efforts should be made to improve the upstream and downstream industrial chains, enhance the research and development capacity of new vaccines, accelerate the construction of a rapid response system for major infectious diseases, strengthen frontier basic research, and enrich product pipelines.

Focus on Kunming and Yuxi to build biotechnology pharmaceutical industrial bases focusing on vaccines, and vigorously develop new biological vaccines, antibody drugs, biological analogues, cell preparations, blood products such as albumin, coagulation factors and immunoglobulin, and other new products of proteins, peptides and nucleic acids. Enlarge and strengthen the existing biotechnology drug enterprises, encourage vaccine enterprises to build digital and intelligent production lines, and improve the production technology level. Guide enterprises in the province to build, acquire and merge R&D institutions at home and abroad, build a quality system, R&D system and production technology system that are in line with international standards, promote the international registration and WHO pre-certification of biological vaccine products, build a vaccine production and supply base that meets international quality standards and a leading domestic monoclonal antibody drug industry base, increase open cooperation with South Asia, Southeast Asia, Africa, Europe and the United States, and open up markets in South Asia, Southeast Asia and the Indian Ocean Rim.

Traditional vaccines: enterprises are encouraged to develop univalent vaccines, multivalent vaccines and multiplex vaccines with attenuated, detoxified and inactivated products based on pathogenic microorganisms and their metabolites, so as to promote the secondary development and upgrading of biological vaccines.

New vaccines: break through the key core technologies such as efficient genetic engineering construction technology of virus species and strains, screening research technology of pathogen antigen components, bacterial polysaccharide-protein binding technology, large-scale animal cell culture technology, new vaccine adjuvant technology, genetic engineering technology, genetic engineering recombination technology, non-human primate model evaluation, and carry out research and development and transformation of new vaccines such as nucleic acid vaccine, synthetic peptide vaccine, genetic engineering vaccine and recombination vaccines. Increase the forward-looking research and development of mRNA technology in the prevention and treatment of infectious diseases, AIDS, genetic diseases, rare diseases, tumors and other major diseases.

Antibody, protein and nucleic acid drugs: develop monoclonal antibody drugs, neutralizing antibodies, bispecific antibodies, antibody-coupled drugs (ADC), biological analogues, recombinant protein drugs, polypeptide drugs and nucleic acid drugs for diseases such as tumor, immune system, cardiovascular and cerebrovascular diseases and infections.

Animal vaccines: Encourage the research and development of veterinary vaccines such as Class A epidemic vaccines, multi-animal co-morbid vaccines, vaccines for cattle and sheep, vaccines for pigs, vaccines for poultry, and vaccines for pets.

Cell preparation: within the scope permitted by policies and regulations, encourage and standardize the research and development of cell therapy products including stem cells and immune cells; We will carry out research on a series of standards and technical systems such as preparation, quality inspection and safety evaluation of clinical-grade cell products and derivatives, improve their safety, effectiveness and quality controllability, and accelerate the research on clinical application norms of cell therapy.

Blood products: introduce and develop blood products, focusing on the development of coagulation factors, thrombin, human albumin, human fibrinogen, immunoglobulin and other products. Within the scope permitted by the policy, the layout of plasma raw materials will be increased by adding plasma collection stations.

Other biotechnologies: Accelerate the construction of a synthetic biotechnology innovation system, support the research on genome design and synthesis, and provide technical support for basic research on new biological treatment methods, vaccines, materials and disease control.

Make use of the advantages of genetic resources in our province to develop the biomedical industry of non-human primates and carry out research on the protection and rational utilization of human genetic resources; Carry out research on transplant organ cultivation technology and xenotransplantation technology.

(2) Modern Chinese medicine represented by formula granules.

Focus on the quality upgrade, secondary development, new indications mining, economic evaluation, clinical value-oriented research on safety and clinical efficacy evaluation of traditional Chinese medicine, and innovative drug development of traditional Chinese medicine, and make efforts in the research on local standards of characteristic Chinese herbal pieces, quality standards that meet the requirements of Pharmacopoeia, effectiveness and safety evaluation, production process improvement, and automation, intelligence and information construction of production and processing.

Focus on Kunming, Yuxi, Chuxiong, Dali, Wenshan, Baoshan, Pu ‘er, Honghe and other cities to develop modern Chinese medicine. On the basis of medicinal animal and plant resources such as Panax notoginseng, Erigeron breviscapus, Gastrodia elata, Paris polyphylla, Periplaneta americana, leech, etc., and taking the development of characteristic ethnic medicines such as Yi medicine and Dai medicine as a breakthrough, we will speed up the cultivation of large varieties of modern Chinese medicine (ethnic medicine) preparations, create a number of brand products, and make Yunnan medicine industry bigger and stronger. Based on classic prescriptions, proven prescriptions and hospital preparations, we will develop innovative Chinese medicine (ethnic medicine) and epidemic prevention preparations covering the whole life cycle of prevention, treatment and rehabilitation for the prevention and treatment of major diseases such as malignant tumors, cardiovascular and cerebrovascular diseases, emerging infectious diseases and AIDS. Guided by clinical value, we will carry out material basic research, safety evaluation of traditional Chinese medicine and clinical efficacy research, and explore the construction of a three-in-one evidence system of "Chinese medicine theory-human experience-clinical trial" for the research and development of new traditional Chinese medicine. Adopt modern biotechnology, advanced pharmaceutical technology and preparation technology to promote the application of biocatalysis and transformation, refining, extraction and separation in the research and development of modern Chinese medicine.

In Kunming, Chuxiong, Wenshan, Zhaotong, Pu ‘er, Baoshan, Lijiang and other major producing areas, the production base of Chinese herbal pieces will be laid out, with the focus on building Chuxiong into a national first-class industrial base of Chinese herbal formula granules. Form more than 10 brand enterprises producing Chinese herbal pieces and local standards for formula granules of more than 100 varieties. Strengthen cooperation with state-level research institutions and well-known domestic enterprises, carry out research on quality standards of traditional Chinese medicine formula granules and upgrade the processing and production technology, and establish a quality standard system, a safety evaluation system and a clinical trial research system for traditional Chinese medicine decoction pieces that meet the requirements of People’s Republic of China (PRC) Pharmacopoeia and international standards. Carry out the equivalent test and production technology research of formula granules, and establish the processing technology and quality evaluation method of traditional Chinese medicine decoction pieces combined with modern science and technology. Develop new modern technologies, equipment and facilities such as extraction, concentration, drying and granulation, apply blockchain traceability technology to improve online quality control, establish a traceability system for processing and production of Chinese herbal pieces, and build a number of intelligent production lines of Chinese herbal pieces with advanced technology and strict quality control.

We will build a research center for ethnic medicine focusing on Yi medicine, Dai medicine and Tibetan medicine, systematically excavate and sort out ethnic medicine documents of Yi, Dai, Tibetan, Naxi, Wa and Hani nationalities, and carry out clinical application of traditional ethnic medicine therapy and its ancillary products and theoretical research on ethnic medicine. Relying on ethnic medicine resources, develop external preparations. Strengthen the research and development and clinical application of preparations in ethnic medicine hospitals, and carry out research and development of new ethnic medicine with clear mechanism, high technology content and reliable curative effect.

Build a characteristic industrial cluster of Sanqi, and build Sanqi into the first brand of traditional Chinese medicine in China. We will build a Sanqi industrial innovation consortium with enterprises as the main body, and gather superior resources inside and outside the province to carry out key technology research and transformation and application of achievements. Develop innovative drugs for prevention, treatment and rehabilitation of cardiovascular and cerebrovascular diseases; Focusing on the large varieties and exclusive varieties of traditional Chinese medicine (ethnic medicine) such as Sanqi series and Dengzhanhua series, we will increase the re-evaluation after listing and the secondary development of "new use of old drugs", and carry out research on the combination of traditional Chinese and western medicine such as "Xuesaitong+aspirin"; Strengthen the biosynthesis and application of panax notoginseng saponins, scutellarin, Paris polyphylla saponins and other extracts; Carry out research on the processing technology and technology of traditional Chinese medicines such as Panax Notoginseng while fresh, and formulate standards for new-type decoction pieces such as formula granules and powder decoction pieces of characteristic varieties such as Panax Notoginseng and Gastrodia elata which meet the standards of People’s Republic of China (PRC) Pharmacopoeia; To study and formulate EU Pharmacopoeia standards for Sanqi formula granules, panax pseudo-ginseng and other products, so as to enhance the international popularity and influence of Sanqi.

Regional cooperation in the research and development of traditional Chinese medicine (ethnic medicine) should be carried out for South Asia and Southeast Asia, international multi-center clinical trials and international registration of traditional Chinese medicine preparations with good clinical effect and clear mechanism of action should be carried out, and a modern standard production system and quality evaluation system of traditional Chinese medicine should be constructed according to international standards.

(3) Health products based on natural extracts.

Continue to strengthen the research on the material basis of effective active ingredients of animals and plants, increase the development and application of extracts, strengthen the development of high-quality health products, and cultivate brand products with market competitiveness and scale effect.

Focus on Kunming, Yuxi, Chuxiong, Pu ‘er, Xishuangbanna, Lijiang, Wenshan and other cities to build health product research and development and production bases, and develop high value-added health products. Focus on health care products and daily chemical products such as Sanqi series, Dendrobium series and microalgae series, and build a number of brand products with sales income exceeding 1 billion yuan. Introduce well-known enterprises at home and abroad, cultivate some leading enterprises, and promote Yunnan’s health products to South Asia and Southeast Asia.

Construction of Yunnan laboratory for extracting characteristic plants. Focusing on plant extraction and scientific and technological innovation in the whole industrial chain of health products, we will systematically carry out basic research, product development and achievement transformation, and build a platform for functional evaluation and inspection of health foods and cosmetics. Using modern biotechnology, we will strengthen the research on the efficacy and application of animal and plant-derived ingredients, cultivate and expand a number of intensive processing backbone enterprises in the main raw material producing areas in view of the needs of food, medicine, health care products, daily chemical products, feed products and other related industries, and promote the extraction and processing of characteristic Chinese herbal medicines such as Panax notoginseng, Periplaneta americana and leech, as well as the raw materials of characteristic health products such as stevia rebaudiana, eucalyptus globulus, marigold, maca, rose, microalgae and aloe, and research and development. Improve the extraction and separation technology and quality level of panax notoginseng saponins, breviscapine, tea polyphenols, coenzyme Q10, paclitaxel, borneol and other extract products, as well as eucalyptus oil, citronella oil, rose oil, rosemary and other essence and fragrance products. Taking notoginseng, gastrodia elata, Dendrobium nobile, Polygonatum sibiricum, Amomum villosum and other medicinal and edible Chinese herbal medicines as raw materials, and special biological resources such as microalgae, Moringa oleifera, walnuts and flowers as raw materials, we have researched and developed various health products such as medicated diet, medicated wine, medicated tea and drinks, as well as a series of health foods, aromatic products and daily necessities with the functions of resisting oxidation, losing weight, enhancing immunity, relieving anxiety, relieving depression, assisting in improving memory and caring skin. Focus on developing and producing a batch of formula foods with strong pertinence and high patient acceptance, which are suitable for surgery, nephrology, oncology, pediatrics and geriatric rehabilitation.

Improve the development level of Panax notoginseng extract. In-depth study of extracts from different parts such as flowers, stems, leaves, roots, etc., and development of Sanqi series health food, special diet products, oral care, medical beauty skin care and other daily necessities in different dosage forms such as tablets, capsules and oral preparations, enriching product structure and expanding application fields; Improve the extraction technology and product quality level of panax notoginseng saponins, polysaccharides and panax notoginseng elements; Study and formulate international standards for the extraction of characteristic raw materials such as Panax notoginseng, and accelerate the internationalization of Panax notoginseng.

2. Rapid development areas

(1) Chemical drugs

Further improve the industrial chain, improve the research and development capabilities of original drugs and generic drugs, and improve the research and development level of high-end preparations.

Focus on Kunming, Chuxiong and other cities to build R&D and production bases for chemical drugs and chemical raw materials, and carry out R&D and industrialization of innovative drugs, improved new drugs, generic drugs and chemical raw materials.

Strengthen the joint development of "intermediates+APIs+chemicals". Improve the production technology of platinum anti-tumor raw materials and steroid hormone raw materials. Encourage enterprises to buy varieties with high clinical value at home and abroad and enterprises with great development potential to enter Yunnan for development. Develop chemical raw materials, auxiliary materials and packaging materials industries in areas with resources and environmental carrying capacity, and develop a number of chemical synthetic drugs with characteristics, potential and competitiveness. Strengthen exchanges and cooperation with Israel, India and other countries in the research and development of generic drugs, and explore the construction of an international cooperation base for the research and development of generic drugs.

Guide key enterprises and scientific research institutions to focus on the development of innovative drugs for major diseases such as malignant tumors, cardiovascular and cerebrovascular diseases, diabetes, mental diseases, viral infections, etc., especially chemical innovative drugs and improved new drugs with new targets and new mechanisms of action. Carry out research and development of high-end preparations, develop new dosage forms with good clinical substitution for varieties and dosage forms that are clinically necessary and have great side effects, and promote the research and development of sustained and controlled release, targeted, transdermal, mucosal and carrier drug delivery systems. Develop Yunnan plant resources, discover and develop new natural chemical drugs. To carry out the imitation of drugs needed for the treatment of major infectious diseases and rare diseases, drugs needed for the disposal of public health emergencies, drugs used by children, and original drugs whose patents are about to expire. Carry out research and development and green production technology innovation in the fields of chemical raw materials and pharmaceutical intermediates; Carry out the construction of the process technology system for the biosynthesis of important pharmaceutical monomer compounds such as panax notoginseng saponins and breviscapine.

(2) Medical devices

Give full play to the advantages of China (Yunnan) Pilot Free Trade Zone (hereinafter referred to as FTZ) and Border Economic Cooperation Zone, speed up the construction of medical device production and trade system for South Asia and Southeast Asia, develop high-tech and high value-added products, and establish an effective linkage mechanism between medical institutions and medical device industry.

We will build medical device industrial parks in Central Yunnan New District, Qujing, Yuxi, Free Trade Zone and Border Economic Cooperation Zone, build medical device R&D and production, inspection and testing, and trade distribution bases for South Asia and Southeast Asia markets, and build the most complete medical device industrial park in Southwest China.

In view of the market demand in South Asia and Southeast Asia, we will introduce domestic and foreign leading or advantageous enterprises in high-end medical devices and biomaterials to build medical device production bases and supporting industrial chains, cultivate high-end medical device enterprises, and promote the development of upstream and downstream industries of medical devices. Support the construction of a production base that meets the quality management standards for medical device production, build a public R&D and production platform for medical devices, build a high-grade medical device life-cycle detection technology service platform based on units with good foundation, and attract enterprises, research institutions, talent teams and technological achievements to Yunnan to carry out the transformation and industrialization of achievements. We will build a number of leading enterprises in the production of in vitro diagnostic reagents, dentures and disposable infusion devices, and promote the development of industries such as medical devices, new biomaterials, high-end pharmaceutical packaging materials and high-quality pharmaceutical excipients.

Develop technologies and products such as gene detection, biological detection chip and in vitro immunodiagnosis, and develop in vitro diagnostic equipment and reagents such as major emerging infectious diseases and tumor diseases; Accelerate the research and development of new biomaterials, and carry out research and development of new biomaterials such as biomedical materials, tissue engineering materials, bio-based materials and medical and health materials; Carry out research and development and production of high-end consumables such as orthopedic instruments, and build a production base of high-end orthopedic consumables in southwest China; Carry out research and development of TCM diagnosis and treatment instruments and equipment, rehabilitation instruments and equipment, and sports therapy equipment with ethnic characteristics; Carry out the development and industrialization of "big data+artificial intelligence+medical care" instruments and equipment, and develop digital and multifunctional mobile monitoring equipment and wearable products, rehabilitation AIDS and optometry-related products.

(3) Veterinary drugs

Further guide enterprises and scientific research institutions, strengthen investment in veterinary drug research and development, enhance the research and development ability of veterinary drugs, and give full play to the advantages of resources to develop innovative products of veterinary drugs.

Strengthen the cooperation between animal medicine enterprises and scientific research institutions inside and outside the province, and develop or introduce a new generation of animal vaccines and innovative products for veterinary medicine. Improve the quality and production capacity of a number of veterinary drugs, such as bovine O-type and A-type foot-and-mouth disease inactivated vaccine, pig O-type foot-and-mouth disease inactivated vaccine, pig double O-type foot-and-mouth disease inactivated vaccine, hog cholera live vaccine (subculture cell source), piglet paratyphoid, Newcastle disease and so on.

Focus on Kunming, Baoshan, Dali and other cities with veterinary drug industry base to actively develop veterinary drug industry. Increase the research and development of livestock and poultry disease prevention vaccines and pet vaccine products such as cattle, sheep, pigs and chickens; Develop a batch of veterinary traditional Chinese medicine preparations with traditional Chinese medicine as raw materials, which can replace antibiotics, carry out veterinary drug imitation research, develop feed drug additives, improve the self-sufficiency rate of veterinary drug production, and actively expand the market in South Asia and Southeast Asia.

(2) To improve quality and accelerate the construction of high-quality raw material bases for Chinese herbal medicines.

Highlight the construction of standardized planting (breeding) bases for Chinese medicinal materials, adhere to the principle of quality first, control the planting scale, innovate the planting mode, promote the original habitat planting, improve the quality of medicinal materials, and scientifically develop large varieties of raw materials such as Panax notoginseng, Erigeron breviscapus, Paris polyphylla, Gastrodia elata and Dendrobium. At the same time, give play to ecological advantages, actively introduce domestic and foreign high value-added medicinal varieties into Yunnan to build a high-quality raw material planting and processing base. Make good use of domestic and foreign resources and markets to build Yunnan into a national raw material base for high-quality natural medicines and health products.

1. Breeding excellent provenances and developing the fine variety industry of Chinese herbal medicines.

In order to promote the sustainable development of Chinese herbal medicine resources, the collection and evaluation of germplasm resources, screening of high-quality provenances, breeding of new varieties and breeding of improved varieties will be carried out around the backbone medicinal materials and rare and endangered Chinese herbal medicines, and the industry of improved varieties of Chinese herbal medicines will be developed. In view of the problems such as source degradation, we will strengthen the domestication and planting of Chinese herbal medicines and the breeding of improved varieties. Strengthen the investigation, collection, identification, preservation and artificial domestication and cultivation techniques of important rare and precious wild raw material germplasm resources such as Fritillaria cirrhosa, Euphorbia Humifusa, Rhizoma Curculiginis, Rhubarb and Dragon’s Blood, and protect the germplasm and genetic resources. In Wenshan, Zhaotong, Chuxiong, Dali, Lijiang, Pu ‘er, Baoshan and other authentic Chinese herbal medicine producing areas and suitable planting (breeding) areas, 50 breeding bases of authentic superior Chinese herbal medicines, 100 guaranteed nursery bases of Chinese herbal medicines and 100 standardized planting (breeding) bases will be upgraded, and a number of Chinese herbal medicine seed and seedling enterprises will be built, with emphasis on cultivating more than 10 high-quality seed and seedling management companies. Relying on the National Nature Reserve, conservation zone, a Chinese herbal medicine, will be built, and more than two protected areas for endangered and rare wild medicinal plants and animals will be planned, and more than 10 wild breeding bases for endangered and rare genuine medicinal materials from Yunnan will be built to provide support for the rapid development of raw materials industry for health products.

2. Strengthen the construction of high-quality raw material bases and build high-quality Chinese herbal medicine planting areas.

Build the "first workshop" of biomedical industry with the concept of green development. According to GAP standards, develop rural areas to revitalize the "one county, one industry" Chinese herbal medicine planting (breeding) industry. Innovate the planting (breeding) mode and vigorously develop "green planting", "ecological planting", "under forest planting" and "imitation of original habitat planting" of Chinese herbal medicines. Encourage domestic and foreign enterprises to build a "pharmaceutical park" in suitable areas of Yunnan, and accelerate the formation of a situation in which leading enterprises lead, bases are standardized and the province develops in an orderly manner. Cultivate a number of well-known enterprises and high-quality raw material varieties, and build a standard library of reference materials for Chinese herbal medicine varieties. Cooperate with neighboring countries to protect and organize traditional medicinal resources in South Asia and Southeast Asia, popularize planting techniques and carry out overseas planting. Strengthen the research and development and application of advanced equipment for planting Chinese herbal medicines, and improve the modernization level of planting (breeding) Chinese herbal medicines. Cultivate original bulk and regional comprehensive primary processing bases of Chinese herbal medicines, and lay out and build regional inspection and testing platforms.

Give full play to the advantages of Yunnan’s ecological environment, national culture and tourism industry, and promote the construction of a number of Chinese herbal medicine health industrial parks (manors) including standardized cultivation (breeding), food culture, health experience, leisure and health preservation, and popular science propaganda, with emphasis on building more than 10 well-known manors.

3. Accelerate the improvement and efficiency of "the hometown of Yunnan medicine" and build the brand of "Yunnan medicine"

Relying on the "Hometown of Yunyao", we will promote the construction of more than 60 standardized, large-scale and standardized planting (breeding) areas of high-quality Chinese herbal medicines, improve the standards of authentic Chinese herbal medicines, study and formulate a number of domestic and international standards for raw materials of health products, expand the scale of green planting and ecological planting of Chinese herbal medicines, standardize the whole process management of raw material planting (breeding), and build a quality monitoring network and traceability system covering the main producing areas of Chinese herbal medicines in the province. Build a green production technology promotion system, a production processing technology system, a quality evaluation system and a traceability system of the whole industry chain, and build a "Top Ten Yunyao" brand. We will carry out basic research on pharmacology, medicalization, efficacy and safety evaluation of Chinese herbal medicines, and develop a number of new food raw materials.

Build Sanqi into a national demonstration variety of Chinese herbal medicine intelligent agriculture. Improve the technology and level of green planting, undergrowth planting and original habitat planting of Panax notoginseng, and improve the supply capacity of high-quality and high-end products. Around the breeding, planting, processing, warehousing and other links of improved varieties of Panax notoginseng, we will build a comprehensive and domestic leading big data platform for intelligent agriculture of Panax notoginseng, and build a digital management and service system for seed and seedling quality evaluation, monitoring and early warning of pests and diseases, intelligent diagnosis, processing of origin, warehousing and logistics, quality inspection, product traceability and so on.

(three) to expand the market and accelerate the improvement of the business system of biomedical products.

Based in Yunnan, facing the whole country, South Asia, Southeast Asia and the Indian Ocean Rim, with the help of internet plus, big data, cloud computing and other modern technical means, we will give full play to the role of free trade zones and border economic cooperation zones, vigorously carry out internal and external cooperation, and build a business system for biomedical products with the focus on market system construction, enterprise management informationization and international business development.

1. Build a regional circulation system

Focusing on free trade zones and border ports, we will lay out and build a number of modern warehousing and logistics centers for biomedical products in all provinces, cities and key counties, cities, districts and border port cities such as Hekou and Ruili, build regional pharmaceutical wholesale and distribution centers, build cold chain logistics, and improve the supply guarantee system for pharmaceutical and health products in Yunnan. High-level construction of Yunnan Chinese herbal medicine trading center, enlarge and strengthen Wenshan Sanqi, Zhaotong Tianma and other regional characteristic Chinese herbal medicine markets, build a futures market for bulk medicinal materials and scarce medicinal materials, and cultivate a regional distributed trading market for fresh medicinal materials. Strengthen the supervision of Chinese herbal medicine market, standardize the access management of Chinese herbal medicine market, and establish a quality inspection, public warehousing and quality traceability system.

2. Promote the development of new logistics formats

Promote the "internet plus" business model, encourage drug circulation enterprises to use the Internet and Internet of Things technology, introduce third-party service organizations such as insurance and logistics, provide extended services such as online pharmacies and drug distribution, and build an information management system covering the whole province’s business circulation. Taking the Chamber of Commerce as the main body, we will jointly build the "Yunyao Information Network" and "Yunyao Database" to build the Yunnan pharmaceutical e-commerce trading platform. Develop the platform economy of "internet plus Traditional Chinese Medicine+Traditional Chinese Medicine+Health Service" and build a new format and new model economy of Chinese medicine industry.

3. Broaden the market channels of Yunyao.

Strengthen cooperation in commercial production, encourage commercial circulation enterprises inside and outside the province to sell Yunnan products, guide commercial circulation enterprises to build production and marketing alliances with raw material planting enterprises and pharmaceutical and health care products production enterprises, and provide market information and sales channels for production enterprises. Develop a number of specialized institutions that exchange and cooperate with domestic and foreign countries, and hold various seminars, exchanges and exhibitions. Encourage business circulation enterprises in the province to become bigger and stronger, and lead production enterprises, especially small and medium-sized enterprises, to expand domestic and foreign markets.

Fourth, the main measures

(1) Vigorously implement accurate investment promotion.

In-depth implementation of the "multiplication" plan of market players, focusing on biotechnology drugs, modern Chinese medicine, chemical pharmaceuticals, health products and other fields, aiming at the top 500 international companies, the top 100 biomedical companies and leading enterprises in the industry, and carrying out accurate investment promotion. Implement the drug marketing license holder system, and introduce innovative achievements holders such as biotechnology drugs, innovative Chinese medicines and chemical medicines to Yunnan to carry out achievements transformation and industrialization. Introduce and develop serum-free cell culture medium, affinity filler medium, ultrafiltration membrane, disposable reaction bag and other upstream and downstream supporting enterprises of biological products represented by vaccines to enter Yunnan for development. Introduce Chinese herbal pieces and health products processing enterprises represented by formula granules into Yunnan to build a raw material base, research and development production base and extend the industrial chain of Chinese herbal medicines. Implement the medical device holder system, give full play to the advantages of free trade zone and border economic cooperation zone, introduce medical device R&D and production enterprises to Yunnan, and build a medical device production and circulation base for South Asia and Southeast Asia. Introduce chemical raw material medicine enterprises into Yunnan for development in areas with resources and environmental carrying capacity. In combination with the introduction of science and technology into Yunnan, we will actively promote the "four landings" of talent teams, scientific and technological enterprises, scientific and technological achievements and innovation platforms, and strengthen the introduction of CRO (contract research and development institutions) and CMO (commissioned production institutions).

(2) Accelerate major projects.

Implement special projects for the development of biomedical industry, organize and implement a number of key projects to support and lead the development of biomedical industry. Relying on leading enterprises and R&D institutions with strong R&D capabilities, we will organize and plan a number of major projects combining "Industry-University-Research" for the development needs of key areas of biomedicine. With the goal of leading enterprises and key brand products becoming bigger and stronger, we will implement a number of quality improvement and efficiency improvement projects through digital and intelligent technological transformation and secondary development. With the goal of building industrial clusters, support key cities, key parks and key enterprises to plan and implement a number of key projects. Encourage the park to plan a number of preliminary projects and implement a number of key projects around infrastructure construction, key industrial bases construction and major scientific research platforms construction, and strengthen tracking management and service guarantee.

(C) focus on cultivating leading enterprises

Implement the cultivation plan of leading enterprises, and comprehensively improve the comprehensive competitiveness of pharmaceutical enterprises. In accordance with the principle of "one thing, one discussion, one enterprise, one policy", we will enlarge and strengthen leading enterprises, cultivate a number of large enterprise groups with international influence, develop and expand a number of key enterprises, support the development of small and medium-sized enterprises, and form enterprise clusters. In the fields of traditional Chinese medicine, biotechnology medicine, chemical medicine and health products, select a group of enterprises with good growth to focus on cultivation. Support enterprises to build raw material bases and production bases around the industrial chain, and improve the level of automation, intelligence and informatization of enterprises. Carry out the listing cultivation of biomedical enterprises, and continue to promote the listing progress of biomedical "golden seed" enterprises. Support enterprises to take capital, technology, brand as the link, through mergers and acquisitions, agreement transfer, joint restructuring, holding shares and other ways to carry out mergers and acquisitions, improve industrial concentration.

(4) Continuously improve the innovation capability.

Focusing on the fields of vaccines, antibody drugs, cell products, modern Chinese medicine, formula granules, chemical drugs, health products, extracts, etc., we will upgrade and build a number of industrial public service platforms and specialized research and development platforms, form a perfect biomedical research and development and technical service chain, and continuously improve the ability of biomedical innovation. Keep a close eye on the commanding heights of industry technology, increase investment in applied basic research, and reserve a number of advanced and applicable technologies and achievements; Adopt the innovative project organization mode of "unveiling the list", aim at the major needs of the industry, break through key technologies, formulate new standards, develop new products and upgrade new processes. With enterprises as the main body, we will build a number of R&D and service platforms such as key laboratories, technology innovation centers, engineering research centers, enterprise technology centers and industrial technology innovation platforms in conjunction with well-known expert teams and scientific research institutions at home and abroad. Promote the construction of the State Key Laboratory of Biomedicine for Non-human Primates, accelerate the construction of Yunnan Laboratory for Extraction of Characteristic Plants, build a new vaccine technology innovation system, and improve the research platforms such as natural drug screening, research on patent medicine, drug safety evaluation (GLP), drug pilot test, drug clinical evaluation platform (GCP) and bioequivalence test. Construction of provincial clinical medical research centers and a number of national clinical medical research sub-centers. Cultivate and introduce several CRO institutions. Promote and build a platform for big data and digital applications around the biomedical industry chain.

(5) Building professional parks with high quality.

With Kunming as the center and Yuxi, Chuxiong, Wenshan, Qujing, Baoshan, Honghe and other cities as the focus, a number of biomedical industry specialized parks covering the whole province will be built. Focus on promoting Kunming National Bio-industrial Base, Yunnan Central Traditional Chinese Medicine Natural Medicine Economic Circle, Yunnan Central Medical Device Industrial Park, Kunming and Yuxi Bio-vaccine R&D and production bases, International Medical Health City, Chuxiong Traditional Chinese Medicine Formula Granule Industrial Base, Wenshan High-tech Industrial Development Zone, Tengyao Industrial Park, Pu ‘er Biomedical Industrial Park, Honghe Biomedical Industrial Cluster, Qujing Malong Medical Device Emergency Industrial Park and other specialized parks and clusters. Based on the evaluation of the carrying capacity of resources and environment and the suitability of land and space development, chemical raw material medicine parks will be developed in Kunming, Chuxiong and other areas that meet the relevant policy requirements of chemical parks. Promote the gathering of projects, funds, talents and other elements in the park, strengthen the construction of public R&D and service platform, industrial incubation, infrastructure, industrial facilities and human resources conditions in the park, and form a regional specialized park integrating research and development, enterprise incubation, manufacturing and logistics distribution. Strengthen cooperation with biomedical industrial parks in Beijing-Tianjin-Hebei, Yangtze River Delta, Pearl River Delta and other regions, attract large domestic and foreign pharmaceutical enterprises, scientific research institutions and teams, CRO institutions and CMO institutions to settle in the parks, promote industrial agglomeration development, vigorously promote the construction of Kunming Great Health Industry Demonstration Zone, and build Kunming and Yuxi into important bases and agglomeration areas for modern biomedical production and research, and Chuxiong, Wenshan and other cities into important bases for modern Chinese medicine industry.

(6) Accelerate the training and introduction of talent teams

Adhere to the problem orientation, deploy the talent chain around the industrial chain and innovation chain, promote all kinds of talent training and introduction programs to the biomedical industry, further strengthen the training and introduction of high-level talents, and introduce high-end management talents, leading scientific research talents, high-level technical talents and innovative teams through multiple channels. Innovate training methods, train all kinds of talents, expand the enrollment scale of biomedical related majors in colleges and universities, and establish specialized talent training bases relying on qualified colleges and universities. Encourage social capital to set up vocational colleges and training institutions, promote school-enterprise cooperation, jointly cultivate and improve the quality of employees, and focus on cultivating a number of scientific and technological research and development talents, enterprise management talents, marketing talents, licensed pharmacists, quality management, testing and consulting service talents. Encourage the park to set up special funds for talents to provide more powerful talent support for the high-quality development of biomedical industry.

(7) Focus on building the brand of Yunyao.

Focus on the superior products such as vaccine series, Sanqi series and Dengzhanhua series, and build the brand of "Yunyao". To build a biological vaccine brand, we should build a specialized vaccine industry park, build a vaccine research and development system, develop innovative vaccine products, and promote the international development of vaccines. Extend the industrial chain of large varieties of Chinese herbal medicines such as Panax notoginseng, Erigeron breviscapus, Paris polyphylla, Dendrobium, Gastrodia elata, cultivate a number of large varieties of Chinese herbal medicines, and create geographical indication protection varieties. Develop ethnic resources of traditional Chinese medicine, develop and expand a number of dual-purpose varieties of traditional Chinese medicine, and promote the formation of a number of brand products such as Chinese herbal pieces, extracts, health foods and functional cosmetics. Implement the promotion action of famous Yunnan medicine products, give play to the leading role of the propaganda department, and form a publicity system with the participation of the government, enterprises and social organizations. Encourage enterprises to carry out various forms of publicity and promotion activities to publicize the advantages, characteristics, achievements, enterprises, brands, products and people of Yunnan’s development of biomedical industry. Build a brand display platform through various trade fairs such as South Expo and Drug Fair.

V. Guarantee conditions

(A) to strengthen organizational leadership

Improve the bio-pharmaceutical industry promotion mechanism, compact work responsibilities, hold regular meetings, analyze industrial development, study industrial policies, deploy promotion work, coordinate and solve key problems in the development of key enterprises and major projects, and promote vertical linkage at the provincial, prefecture and county levels. Further improve the horizontal linkage mechanism of provincial departments, enhance the joint efforts of all departments to promote the development of biomedical industry, and jointly create a good environment to promote the high-quality development of biomedical industry in Yunnan. An expert advisory committee on biomedical industry composed of senior experts in relevant fields inside and outside the province was established to provide strategic advice on the frontier situation, industrial analysis, innovation ability, regional layout, key investment promotion and policy design of Yunnan biomedical industry.

(2) Increase policy support.

Focusing on the research and innovation of new products, achievements transformation, market development and innovative service system construction in the fields of biotechnology drugs, modern Chinese medicine, chemical drugs, medical devices and health products, we will coordinate financial funds, increase investment and refine specific measures to support the innovation and development of biomedical industry. To obtain the national major new drug creation science and technology projects, the national key research and development plan related key projects, according to the law and regulations to give supporting support. Support for key core technology research and key new product development, comprehensive use of open competition, publicity system, horse racing system, directional selection and other ways to organize major innovation projects. Study and formulate policies and measures to support the development of biomedical industry in the free trade zone, and help Yunnan biomedical industry to go out and introduce. Incorporate key projects and major projects involving industrial development into relevant national development plans and strive for national policy support. Actively strive for the inclusion of superior and characteristic drugs in the national basic medical insurance drug list and the national basic drug list. Encourage all localities to adopt the form of "government subsidies, enterprises making profits and people buying" to promote the project of biological vaccines benefiting the people. Deepen the "streamline administration, delegate power, strengthen regulation and improve services" reform and promote the development of industrial agglomeration.

(3) Overall factor guarantee

Through scientific planning, revitalizing stocks, introducing increments and other ways, we will further expand the development space of biomedical industry, and encourage industrial parks to build standardized factories to meet the needs of biomedical R&D and production enterprises on the basis of meeting the requirements of land and space planning and environmental assessment at all levels. Overall balance of land use, electricity consumption, water consumption, sewage and other indicators, scientific planning and layout of biopharmaceutical and innovative drug production bases. Encourage the park in accordance with the principle of intensive land use, overall planning for the protection of the park urgently needed talent introduction, employment units or park employees accommodation construction land. Focus on advantageous fields and varieties, establish key enterprises and project libraries, give preferential policies to key projects, and streamline examination and approval procedures according to laws and regulations.

(D) Expand financing channels

Give full play to the role of provincial financial control group industrial investment fund, and guide key cities and parks to set up biomedical industry investment funds. Strengthen cooperation with various investment companies, banks and other financial institutions, and adopt various ways and mechanisms such as listing financing, equity investment, credit guarantee, risk compensation, bond financing and asset management to promote base construction, product development, achievement transformation and industrialization, enterprise cultivation, brand building and market expansion.

(5) Strengthening digital empowerment

Promote the digitalization of resources, digital industrialization and industrial digitalization in the biomedical field. Apply modern information technologies such as blockchain, big data and artificial intelligence to upgrade the construction of Yunnan biomedical industry big data center, and further improve the production, supply and marketing network of biomedical enterprises, Chinese herbal medicine bases and circulation enterprises covering the whole province. Promote the construction of Yunnan biological resources digital integration center to realize the sharing, trading and calculation of biological resources scientific data. Give play to the role of industrial big data platform, promote data sharing in R&D, production, approval, sales and use, and break down departmental data barriers.

(6) Pay attention to safety and security.

Strengthen the construction of biosafety risk prevention and control and governance system, strengthen the supervision and management of high-risk and medium-risk biotechnology research and development activities, and take effective countermeasures. Give full play to the role of Yunnan Science and Technology Ethics Committee, strengthen overall planning and guidance, strengthen scientific research ethics supervision, standardize all kinds of scientific research activities, strengthen safety training for managers and professional and technical personnel, and ensure the safe and healthy development of biotechnology. We will comprehensively promote the construction of drug safety regulations and standards system, highlight the improvement of supervision efficiency, enhance the ability of drug monitoring and evaluation, audit and inspection, inspection and testing, and intelligent supervision, and realize the mutual promotion of safety supervision and industrial development. Combine the construction of the vanguard of ecological civilization construction, implement the concept of green development, strengthen environmental protection during the development and application of biotechnology products, and ensure ecological security.

(7) Strengthen evaluation and supervision.

Establish a dynamic evaluation mechanism for the implementation of the plan, formulate a task list every year, and regularly supervise the implementation of the plan by the relevant departments of the state, city and province. We will build a supervision and service mechanism for the operation of key enterprises and the construction of major projects, strengthen the operation monitoring of key enterprises and the scheduling, tracking and service of key projects, and promote the early commencement, completion and commissioning of projects.

Attachment: 1. Atlas of Yunnan Biomedical Industry Chain

2. Regional distribution map of "hometown of Yunyao"

3 main indicators, main tasks and key work responsibilities.

Annex 1

Annex 2

Annex 3

The Central Meteorological Observatory continued to release at 18: 00 on November 6.Strong wind blue warning, cold wave blue warning, blizzard orange warning:

It is estimated that from 20: 00 on November 6 to 20: 00 on November 7, some areas in central and northwestern Inner Mongolia, eastern Xinjiang, northern and eastern Qinghai, Hexi, Gansu, Heilongjiang, Jilin, Liaoning and other places will have strong winds with gusts of 7; There will be strong winds of magnitude 7-8 and gusts of magnitude 9 in the eastern Bohai Sea, the Bohai Strait, most of the Yellow Sea, the northern part of the East China Sea, the southern part of the East China Sea, the Taiwan Province Strait, the east of Taiwan Province, bashi channel and parts of the northeastern South China Sea, among which there will be strong winds of magnitude 9 and gusts of magnitude 10 in some parts of the eastern Yellow Sea.

Affected by strong cold air, it is estimated that from 20: 00 on November 6 to 20: 00 on November 7, the temperature in southeastern Inner Mongolia and most parts of Northeast China will drop by 6 ~ 8℃ successively, among which the temperature in some parts of eastern Jilin can reach 10 ~ 12℃. The lowest temperature 0℃ line will be located in the northeast of Hebei, Tianjin, southwest of Shanxi, Guanzhong Plain of Shaanxi and southeast of Gansu. Some areas in central and northwestern Inner Mongolia, eastern Xinjiang, northern and eastern Qinghai, Hexi, Gansu, Heilongjiang, Jilin and Liaoning will have strong winds of 5~6 and gusts of 7; There will be strong winds of 7-8 grades and gusts of 9-10 grades in the eastern Bohai Sea, most of the Yellow Sea, the northern part of the East China Sea, the southern part of the East China Sea and parts of the northeastern South China Sea.

It is estimated that from 20: 00 on November 6 to 20: 00 on November 7, there will be heavy blizzards in parts of northern Jilin and central and eastern Heilongjiang, among which there will be heavy blizzards (20 ~ 24 mm) in the northeastern part of Heilongjiang. The depth of newly added snow in some areas above is 2-10 cm, and the local area can reach more than 12 cm.

The cold wave continues,

Everyone should take precautions.

comeThe State Council client applet,

Just three steps,

You can receive it in time

Meteorological disaster warning reminder!

Scan below and enter ↓

This service is provided by China Meteorological Bureau.

Step 1 enterMeteorological disaster early warningService,

2. Click ""in the upper right corner.+Subscribe to alert notifications”，

3. Allow sendingMeteorological disaster early warning reminder.

Tip: After completing the above three steps, the system will automatically push the meteorological disaster warning reminder issued by the area where you got the last time.

The cold wave struck,

Remember to keep warm!

Recently, the frequent news of sudden death has aroused everyone’s discussion.

Increasing work pressure and faster pace of life make sudden death a health anxiety for many people.

According to the 2020 National Health Insight Report, 53% people were worried about their sudden death. Among the young post-95 s and post-00 s, 7% and 9% people often even worry about their sudden death every day, and this group of people is only in their twenties this year.

But in fact, as long as you master the knowledge of cardiovascular metabolic disease prevention and make a risk assessment of cardiovascular and cerebrovascular diseases, you don’t have to worry too much about the risk of sudden death.

What is cardiovascular metabolic disease?

Cardiovascular metabolic diseases include hypertension, dyslipidemia, coronary heart disease, stroke, etc.The primary cause of death and disease burden of residents in China.

Smoking;

Drinking alcohol;

Unhealthy diet;

Sedentary.

These bad living habits are the main risk factors for the sharp rise of cardiovascular metabolic diseases.

Elevated blood pressure, abdominal obesity, abnormal glucose metabolism, elevated triglyceride (TG) and decreased high density lipoprotein cholesterol (HDL-C), and at least three of these five indicators are abnormal, which can be called increased cardiovascular metabolic risk.

Remarks: Table 2 is taken from the Guidelines for Healthy Lifestyle Prevention of Cardiovascular Metabolic Diseases in China.

Healthy lifestyle

It is an important cornerstone for the prevention and management of cardiovascular metabolic diseases.

For people with increased metabolic risk, no matter whether they are treated with drugs or not, they need to adhere to a healthy lifestyle, including improving diet, controlling weight, quitting smoking and limiting alcohol, and increasing physical activity appropriately after fully evaluating safety.

If you have no abnormal indicators, but still care about your health, you might as well set yourself some small goals:

Go to bed early for ten minutes today;

Eat more vegetables tomorrow;

Challenge not to drink sweet drinks in January;

Stand up and move after working for half an hour;

Have a comprehensive physical examination once a year;

……

The tragedy of sudden death should not be repeated again and again. These small health goals are the first step to self-rescue.

Cardiovascular disease is also the main cause of death in patients with nonalcoholic fatty liver disease (NAFLD). Relevant prevention and treatment guidelines in China suggest that once the diagnosis of NAFLD is confirmed, the metabolic disorder and cardiovascular risk of patients should be evaluated in time.

Writer: Zhang Wei Affiliated Hospital of Hangzhou Normal University

Editing and finishing of Cong Ling takes you to see famous doctors by the team

Some pictures come from the Internet.

Copyright belongs to the original author.

Please contact us if there is any violation or infringement.

4. The king’s position-computer technology python

Using crawler technology to analyze the word frequency of the retrieved information, find the perspective of concern from high-frequency words, and tap the context of national policy changes, and the results are quantifiable.

Fourth, the actual operation

The practical application of the above theory takes the report about Beidou Industrial Park made by Dai Chunchen as an example. The report attracted the attention of senior leaders at that time, and promoted the implementation and changes of relevant industrial policies.

Original link:

Writing process:

1. Determine the topic and find the value

News from the beginning: Xinhua News Agency mentioned that Beidou satellite system won the highest scientific and technological progress award; And the award was awarded to the team, which was the first national highest scientific and technological progress award won by the team.

Discover the value point: According to the interview, there are no enterprises in some Beidou navigation industrial parks and they are vacant.

2. Establish knowledge reserves and build an article framework.

Use different search channels to establish knowledge reserves, determine the general direction through relevant seminars and forum information, and read papers in China HowNet to establish a systematic understanding of the industry and find the conflict point.

3. Find supporting materials and interviewees, and use interviews to support reports.

4. Search and verify information and cross-correlation.

(1) search local government related planning found suspicious.

/Original content/

The interesting detail is that a province in central China has issued a Beidou industrial plan, and three Beidou industrial parks have been set aside in one breath, requiring the three industrial parks to cultivate and introduce more than 500 Beidou enterprises by 2018, with a total industrial scale of more than 60 billion yuan. Another central province put forward the "Thirteenth Five-Year Plan" goal of Beidou application market with a scale of 100 billion yuan.

This is an extremely ambitious goal. Even in the National Medium and Long-term Development Plan for Satellite Navigation Industry, the scale of the national satellite navigation industry in 2020 is only 400 billion yuan. According to the proportion of 60% and 80% of Beidou system in different fields, the final scale of Beidou industry is only 240-320 billion yuan. The indicators of these two provinces have reached more than half of the above data.

Under the background of planning and setting targets in various places, cities and industrial parks compete fiercely for Beidou enterprises and Beidou talents, and the results can be imagined. According to industry insiders, some Beidou industrial parks are actually vacant in different degrees. The first problem they face is that they can’t recruit Beidou projects, and the second is that the recruited projects are "fake Beidou". Such a departure from the original intention of the establishment of the park can be imagined as a waste of government financial resources and land resources.

② Replace the interviewee’s personal subjective viewpoint with the retrieved information: it not only protects the offline interviewee, but also makes the information point more convincing.

/Original content/

As early as 2014, Yang Yuanxi, an academician of the Chinese Academy of Sciences, who took the lead in formulating the National Medium-and Long-term Development Plan for Satellite Navigation Industry, also shouted that he couldn’t understand the situation of Beidou Industrial Park in various places. According to media reports, during the National "Two Sessions" that year, Yang Yuanxi, a member of Chinese People’s Political Consultative Conference, said vehemently that the Beidou Industrial Park in China was blooming everywhere, and each park occupied thousands of acres of land. Many provinces and cities use the signboard of Beidou Industrial Park to enclose land everywhere, and many enterprises are applying for projects and funds from the government in the name of Beidou Navigation.

Yang Yuanxi’s explanation for the root cause of this chaos is the excessive supply of venues. In his view, Beidou industry is a high-tech industry, and there is not much land needed. At present, the domestic Beidou market cannot support the survival of so many Beidou enterprises. This is also the view of many people in the industry.

③ Make logical deduction in the search results, provide exclusive information and unique perspective, and ultimately affect policy decisions.

/Original content/

In China’s blossoming industrial parks, foreign capital, foreign advanced technology and management experience are introduced, which is nothing more than the migration of industries, from 1 to 100. Under this logic, the park provides tax incentives, low-priced land, and facilitates the recruitment of cheap labor. The formation of an industrial chain in the park also enables manufacturing enterprises to save costs.

However, if Beidou Industrial Park is established, most of the imported enterprises are not formed technology and management experience. Most Beidou project teams may have scientific research achievements and intellectual property rights, but how to industrialize and adapt to the market, they still need to explore while doing, and they need to complete the creation of "from 0 to 1".

Fundamentally speaking, they are makers, and Beidou industry is an innovative economy that needs incubation and growth. The growth environment needed by the innovation economy should be closer to the Silicon Valley in the United States-the high concentration of scientific research resources, the concentration of high-quality talents and specialized venture capital. This is quite different from the "three axes" of local governments to develop traditional manufacturing industries.

Five, knowledge points and practical writing skills

Classification of media texts

1. What is the (nature of the incident)-investigation report

2. (Cause) Why-Explanatory report

3. What is the (state)-feature

For example, the feature "After Zero in Beijing" depicts the working and living conditions of some employees after midnight.

4. What will happen?-Explanatory report

5. What should I do?-Comment/Research

At present, media comments have begun to transform into "think tanks", telling readers "what to do" with deeper and more systematic results.

Message/short story writing template: details+core facts+secondary facts+reasons+background+progress.

The first paragraph: details (fascinating, burying suspense): description+discussion+psychological description.

The second paragraph: the core facts (macro-expounding the background and facts of the incident in combination with the officially announced information)

Paragraph 3: Secondary facts (supplementary facts, supporting facts according to eyewitness testimony/other specific events)

Paragraph 4: Reasons (explain actions and changes)

Paragraph 5: Continue to explain the background (earlier events or similar facts show the macro background)

Paragraph 6: Latest progress

END

Director of Operations | Xie Chan

Editor | Chen Xingmeng

Original title: "Senior media people teach you how to search accurately | Media Notes"

Read the original text

The summer heat has passed, but the temperature doesn’t mean to drop. If you are still steaming to death in the hot weather after the summer heat, it’s time to go to Pinduoduo to feel the long-lost coolness.

Pinduoduo’s 10 billion subsidy for summer clearance has officially arrived. The highest 260 yuan large-value coupon package is waiting for you to collect, and then you can enjoy a discount on the coupons of active goods, and give you an ice point price in hot summer!

Get the coupon first when you pass by, and you will never lose money when you get the coupon! As low as, the highest straight drop in the whole series!

If you don’t want to miss this ice cream, just click on the link below and enter and choose your baby.

> > > Click here to go to the main venue of the 10 billion subsidy < < <

As usual, I have carefully compiled a list of good things for everyone, all of which are hot-selling products, and I believe there will be something that will make you feel excited.

In terms of mobile phones, I still recommend the 14 series for everyone. This Pinduoduo summer clearance promotion, the price of iPhone 14 series is:

IPhone14, the summer promotion price is as low as!

IPhone14 Pro, the price is as low as summer!

IPhone14 Pro Max, the summer promotion price is as low as!

IPhone 14 is equipped with a 6.1-inch Retina XDR OLED display with original color display, tactile touch and peak brightness of up to 1200 nits. Internally, iPhone 14 still uses A15 bionic chip, but it provides better performance than.

The iPhone14 Pro has a redesigned original deep camera array, which can provide a unique interactive way of "smart island". The 6.1-inch Super Retina XDR display is brighter and has the function of AOD display. Its A16 chip is the first Apple chip based on 4nm technology.

Click on the link below to go to Apple to buy the iPhone 14 series. .

> > > Click here to go to Apple Special < < <

As for the mobile phone, I would like to recommend the official website price of Glory 90,12gb+256gb, and the price of Pinduoduo’s tens of billions of subsidies for summer clearance promotion only needs.

Glory 90 is designed by Jingyue, equipped with a 6.7-inch 3840Hz UHF dimming quad screen, built-in 5000mAh battery, and supports 66W fast charging. At the same time, it is equipped with a 200 million pixel outsole main camera on the image.

Click on the link below to go to HONOR Subsidy Museum to buy Glory 90. .

> > > Click here to go to HONOR Subsidy Museum < < <

Next is a high-end flagship mobile phone, vivo X90, 8GB+256GB official website price.10 billion subsidies, summer clearance, big price promotion, just!

Vivo X90 is equipped with MediaTek Tianji 9200 processor, with self-developed V2 image chip and ultra-wide ice field cooling system, built-in 4810mAh battery, 120W dual-core flash charging support, and 50MP VCS IMX866 main camera.

Click on the link below to go to the OPPO mobile phone subsidy museum to buy vivo X90. .

> > > Click here to go to vivo mobile phone subsidy museum < < <

It’s a good time to officially play games during the summer vacation. Here we recommend a light and shadow wizard 9 game book from HP, official website price.Pinduoduo’s 10 billion subsidies for summer clearance and promotion activities only cost!

This HP Shadow Wizard 9 is equipped with Intel i7-13650HX processor, NVIDIA RTX 4060 graphics card, 16.1-inch 2.5K 165Hz refresh rate screen, 16GB dual-channel 4800MHz memory and 1TB PCIe 4.0 large-capacity solid state drive.

Click the link below to purchase this HP Light and Shadow Wizard 9. .

> > > click here to buy < < <

In addition to playing games with the game book, the console or console is also a good choice. Here, we recommend the limited edition Switch OLED of the legend of zelda: Tears of the Kingdom, the original price of the Hong Kong version in official website, and the subsidy price for the summer clearance in Pinduoduo.

Switch OLED uses a 7-inch OLED screen and a better speaker. The built-in storage space has also been upgraded from 32GB to 64GB, and the bracket at the back of the fuselage is also larger. The battery life is similar to the previous battery life enhanced version.

Click the link below to purchase this limited edition Switch OLED of the legend of zelda: Tears of the Kingdom.

> > > click here to buy < < <

The weather is hot, and mobile phones are more prone to fever. For those who play mobile phones frequently, you need this one plus 27W freezing point heat dissipation back clip, with the original price in official website and a subsidy of 10 billion yuan for summer clearance.

This one-plus-27W freezing point cooling back clip has 27W ultra-high power full of blood, 1800 square mm super-large cooling plate area, brand-new customized double TEC cooling plate 2.0, temperature difference increased by 1.5, high-energy cooling, and direct filling.

Click on the link below to purchase this one plus 27W freezing point cooling back clip.

> > > click here to buy < < <

In summer, many people have the need to store cold drinks. Here we recommend another refrigerator, Xiaomi 606L cross four-door air-cooled frost-free refrigerator (BCD-606WMFSA), the original price of official website, and a subsidy of 10 billion yuan to clear the house in summer.

Xiaomi 606L cross four-door air-cooled frost-free refrigerator supports the water molecular sieve ecological preservation technology, and the moisturizing fresh-keeping drawer is built with an ecological moisturizing film to control the humidity in the drawer and prevent the water loss of fruits and vegetables. At the same time, the fuselage is as thin as 69cm, and the embedded cabinet is not abrupt, and the integrated home space is more free.

Click the link below to buy this millet 606L cross four-door air-cooled frost-free refrigerator. .

> > > click here to buy < < <

It is the most wonderful thing to come to a bottle of iced drinks in summer. Here we recommend 500ml*15 bottles of alien electrolyte water in a full case, with the original price in official website, and a subsidy of 10 billion yuan for clearing the house in summer.

The alien electrolyte water contains 0 sugar and 0 calories, and the electrolyte is more than or equal to ≥200mg/bottle, which helps to maintain the electrolyte balance in the body and keep the body in a good hydration state. In addition, it is specially added with double vitamins, which has the functions of antioxidation and helping protein to metabolize and utilize.

Click on the link below, and you can go to the summer snack night snack to buy 500ml*15 bottles of this alien electrolyte water. . At the same time, there are many summer delicacies, drinks, beer, crayfish and so on in the summer snack special, and you can choose according to your needs.

> > > Click here to go to the summer supper special < < <

As for fruits, I recommend this sunshine rose as a whole string of sunny Wang Putao qingti, with the original price and 10 billion subsidies for summer clearance.

Sunshine Rose Sunny Wang Putao Qingti pulp is full, crisp and sweet, full of juice, irrigated with natural mountain spring water, naturally mature, with higher sugar and sweeter.

Click on the link below, and you can go to the Treasure Fruit Special to buy this whole string of sunny roses, Wang Putao Qingti. . Of course, if you want other fruits, you can also choose them at the special event.

> > > Click here to go to the Treasure Fruit Special < < <

Finally, Wuliangye 52-degree 500ml×1 bottle of Luzhou-flavor liquor, original price in official website.10 billion subsidies, summer clearance and big promotion activities only need,!

Wuliangye has a brand precipitation of more than a century. The brand-new eighth-generation Wuliangye combines the charm and essence of Wuliangye, with a long aroma, mellow taste, sweet entrance, clean throat and just right coordination.

Click on the link below, and you can go to the famous wine special to start with this Wuliangye 52-degree Luzhou-flavor liquor in 500ml×1 bottle.

> > > Click here to go to the famous wine special < < <

In addition to the products recommended by Xiaobian above, there are more welfare benefits waiting for you in this Pinduoduo’s 10 billion subsidy summer clearance promotion activity. Click on the link below to discover more surprises.

> > > Click here to go to the main venue of the 10 billion subsidy < < <

In addition, what you see in the tens of billions of subsidies are genuine and good goods authorized by major brands, and the quality of products is trustworthy, so friends can buy with confidence.

At present, the activity has been hotly started, so friends should hurry to buy it.

Beijing Zhengban made [2022] No.18

District People’s governments, municipal government commissions, offices and bureaus, and municipal institutions:

　　With the consent of the municipal government, we hereby print and distribute "Several Measures on Dealing with the Impact of COVID-19 Epidemic and Promoting the Smooth Operation of Advanced Manufacturing Industry in this Municipality" to you, please conscientiously implement it in light of the actual situation.

General Office of Beijing Municipal People’s Government　　　　

June 1, 2022　　

Some measures to deal with the influence of COVID-19 epidemic situation and promote the stable operation of advanced manufacturing industry in this city

　　In order to implement the Notice of the National Development and Reform Commission and other departments on Printing and Distributing Several Policies for Promoting the Steady Growth of Industrial Economy (No.273 [2022] of the Development and Reform Commission), adhere to the principle of keeping the word steady, strive for progress in stability, promote the high-end intelligent green development of manufacturing industry, and ensure the economic operation of this Municipality in a reasonable range, the following measures are formulated.

　　First, keep the supply chain of key industrial chains smooth

　　(a) to ensure the smooth and efficient transportation of materials. Conscientiously implement the requirements of the State Council’s joint prevention and control mechanism to deal with the pneumonia epidemic in novel coronavirus "Notice on Doing a Good Job in Keeping Freight Logistics Smooth" (Guo Ban Fa Dian [2022] No.3), implement closed-loop management of "taking and chasing" for truck drivers, and make every effort to get through transportation congestion points to ensure the smooth transportation of people’s livelihood materials and important production materials. Under the premise that the enterprise promises to strictly implement various epidemic prevention and control measures, it will issue vehicle passes for key materials transportation in time and in full, further simplify the handling process and promote online handling. In the area adjacent to Tianjin and Hebei, relying on the existing logistics parks and freight stations, temporary transfer stations and truck drivers’ epidemic prevention service stations will be set up, and various supporting facilities such as loading and unloading equipment and connecting vehicles will be improved to provide nucleic acid detection and antigen detection services for truck drivers. (Responsible units: Municipal Transportation Commission, Municipal Bureau of Economic and Information Technology, Beijing-Tianjin-Hebei Cooperation Office, Municipal Public Security Bureau, Municipal Health and Wellness Commission, Municipal Center for Disease Control and Prevention, Beijing Economic and Technological Development Zone Management Committee, and district governments)

　　(2) Stabilize the supply chain of enterprise industrial chain. Establish a stable industrial chain supply chain coordination mechanism, actively connect with the coordination platform of relevant state ministries and commissions, and strive to include key industries and foreign trade enterprises such as automobiles, integrated circuits, consumer electronics, equipment manufacturing, agricultural materials, food and medicine in the "white list" of national key industrial chain supply chain enterprises. Establish a "white list" of municipal key enterprises, guide enterprises to improve their production toughness, appropriately increase the reserves of production materials and living and epidemic prevention materials, optimize the supply chain and logistics transportation plan, improve the plan for closed-loop production when necessary, strengthen the supply of living materials and infrastructure services for enterprises, coordinate and solve specific difficulties and problems reflected by enterprises in a timely manner, and ensure stable production of enterprises. Encourage enterprises to improve the performance rating of heavily polluted weather through upgrading, and accurately implement differentiated emission reduction measures. Give full play to the role of cross-regional coordination mechanisms such as the coordinated development of Beijing, Tianjin and Hebei, and promote supporting enterprises outside Beijing to resume work and production as soon as possible. Guide leading enterprises in the industrial chain to formulate backup plans or alternative lists of supply chains, encourage leading enterprises to integrate upstream and downstream resources, build a stable supporting consortium, and give certain financial support to those enterprises that are included in the supply chain of leading enterprises in key areas of this city for the first time within the scope of Beijing, Tianjin and Hebei and whose actual performance amount meets the requirements. (Responsible units: Municipal Economic and Information Technology Bureau, Municipal Development and Reform Commission, Prevention and Control Group for Resumption of Work, Beijing-Tianjin-Hebei Cooperation Office, Zhongguancun Management Committee of Municipal Science and Technology Commission, Beijing Economic and Technological Development Zone Management Committee, Municipal Bureau of Ecology and Environment, and district governments)

　　Second, strengthen the protection of land use and energy.

　　(three) to promote the landing of major projects. Strengthen the demand for land for manufacturing projects, and strengthen the district-level overall planning and municipal coordination of the balance index of cultivated land occupation and compensation. Increase the reserve of manufacturing projects, optimize the land supply and approval services for major projects that have been clearly landed, strengthen departmental linkage, urban coordination, pre-trial in advance, and promote parallel promotion, and promote the "land acquisition and construction" model. We will promote the linkage between environmental impact assessment of industrial park planning and project environmental impact assessment, and accelerate the examination and approval of environmental impact assessment of major projects such as energy saving and carbon reduction transformation. Authorized industrial park development enterprises shall, with the consent of the municipal government, give no more than 30% fixed assets investment subsidy support in combination with the important standard factory building projects in the area where they are located. (Responsible units: Municipal Planning and Natural Resources Commission, Municipal Economic and Information Bureau, Municipal Development and Reform Commission, Municipal Housing and Urban-Rural Development Commission, Beijing Economic and Technological Development Zone Administrative Committee, and district governments)

　　(4) Revitalize and upgrade the inefficient industrial space. On the premise of conforming to the functional orientation and planning of the capital, the project implementation unit is encouraged to carry out structural reinforcement, green and low-carbon transformation, application of science and technology scenes, internal and external decoration and other investment transformation for industrial vacated spaces and old factories in key areas by means of independence, joint venture and leasing, and the scope of support will be extended from the central city and sub-center of the city to "three cities and one district" to promote the upgrading of regional manufacturing industry, and the municipal government’s fixed assets investment will support qualified projects. (Responsible units: Municipal Development and Reform Commission, Beijing Economic and Technological Development Zone Administrative Committee and relevant district governments)

　　(5) Strengthen energy security. We will improve the guarantee mechanism for the consumption of renewable energy and electricity, and implement the policy of excluding the consumption of new renewable energy and raw materials from the total energy consumption control. Improve the dual control scheme of energy consumption intensity and total amount in this city, and promote the inclusion of qualified major projects in this city in the scope of energy consumption of major national projects. Ensure the demand for electricity for production of manufacturing enterprises, strictly implement the national electricity price reform policy, integrate differentiated electricity price policies such as differential electricity price, ladder electricity price and punitive electricity price, establish a unified ladder electricity price system for high energy-consuming industries, and do not increase the electricity consumption of stock enterprises with energy efficiency reaching the benchmark level and enterprises under construction and planned to build with energy efficiency reaching the benchmark level, and implement ladder electricity price according to the energy efficiency level gap if they fail to reach it. (Responsible unit: Municipal Development and Reform Commission)

　　Third, increase fiscal and taxation financial support

　　(six) the implementation of value-added tax refund at the end of the period. We will strengthen the tax refund policy for small and micro enterprises at the end of the VAT period. From April 1, 2022, we will extend the policy scope of fully refunding the incremental VAT tax allowance for advanced manufacturing industries to eligible small and micro enterprises (including individual industrial and commercial households) and refund the tax allowance for small and micro enterprises in one lump sum. We will strengthen the policy of tax refund for manufacturing industries at the end of the value-added tax period, expand the scope of the policy of fully refunding the incremental value-added tax allowance for advanced manufacturing industries on a monthly basis to qualified enterprises in manufacturing industries (including individual industrial and commercial households), and refund the stock tax allowance for enterprises in manufacturing industries at one time. (Responsible units: Beijing Municipal Taxation Bureau and Municipal Finance Bureau)

　　(7) Promoting the policy of tax reduction and fee reduction has been effective. Increase the pre-tax deduction of equipment and appliances in small and medium-sized enterprises. According to different depreciation years, small and medium-sized enterprises can choose 100% of the unit value to be deducted before tax in the current year, or 50% of the unit value to be deducted before tax in the current year, and the remaining 50% to be depreciated in the remaining years according to regulations. The scope of small and medium-sized enterprises to which the policy applies includes: first, information transmission industry, construction industry, leasing and business service industry, with the standard of less than 2,000 employees, or less than 1 billion yuan in operating income, or less than 1.2 billion yuan in total assets; Second, real estate development and management, the standard is operating income of less than 2 billion yuan or total assets of less than 100 million yuan; Third, other industries, the standard is less than 1000 employees or operating income of less than 400 million yuan. In the fourth quarter of 2021, the deferred payment period of some taxes and fees will continue to be extended for six months, and in the first and second quarters of 2022, some taxes and fees will be delayed for six months, of which medium-sized enterprises can delay paying 50% of the amount of taxes and fees, and small and micro enterprises can delay paying all taxes and fees. Continue to reduce the "six taxes and two fees" according to the 50% tax rate, and expand the scope of the policy to small and meager profit enterprises and individual industrial and commercial households. Guide enterprises to increase R&D investment, and if the actual R&D expenses incurred in R&D activities of small and medium-sized science and technology enterprises do not form intangible assets and are included in the current profits and losses, on the basis of actual deduction according to regulations,Then add and deduct 100% of the actual amount before tax; Where intangible assets are formed, they shall be amortized before tax according to 200% of the cost of intangible assets. Continue to implement the 1% unemployment insurance rate policy until April 30, 2023. We will extend the policy scope of phased holdover of pension, unemployment and work-related injury insurance premiums to all small and medium-sized enterprises and individual industrial and commercial households affected by the epidemic. (Responsible units: Beijing Municipal Taxation Bureau, Municipal Finance Bureau and Municipal Human Resources and Social Security Bureau)

　　(8) Increase financing support for manufacturing industry. Seize the opportunity of the national policy of 200 billion yuan for scientific and technological innovation and 100 billion yuan for transportation and logistics, and organize enterprises to actively apply for financial support. Establish and improve the assessment and notification mechanism of manufacturing credit, and guide commercial banks to maintain a high growth rate of medium and long-term loans in manufacturing. Do a good job in the industry-finance docking service of manufacturing enterprises, regularly push the information of major manufacturing projects and enterprises in this city to commercial banks, and guide financial institutions to increase their support for high-quality enterprises affected by the epidemic, which has delayed the delivery date and extended the payment time, resulting in difficulties in capital turnover, and prevent blind reluctance to lend, loan withdrawal, loan suspension and loan pressure. Support "specialized and innovative" small and medium-sized enterprises to be listed on the New Third Board and the Beijing Stock Exchange, establish a reserve enterprise resource pool for listing, and do a good job in the gradient cultivation and classification guidance of enterprises. Encourage qualified park infrastructure and new infrastructure projects to participate in the national infrastructure REITs pilot. (Responsible units: Business Management Department of People’s Bank of China, Beijing Banking Insurance Regulatory Bureau, Municipal Financial Supervision Bureau, Beijing Securities Regulatory Bureau, Municipal Bureau of Economy and Information Technology, Zhongguancun Management Committee of Municipal Science and Technology Commission, and Municipal Development and Reform Commission)

　　(nine) to guide all kinds of funds to increase investment in manufacturing industry. Accelerate the implementation of financial funds such as high-tech industrial development funds, strengthen inclusive support methods, and expand policy coverage. Make good use of all kinds of government guidance funds to attract social capital to the advanced manufacturing industry. Optimize the high-tech industrial fund scheme, and increase equity investment in key areas and major projects through direct investment, mergers and acquisitions and the establishment of sub-funds. Accelerate the investment progress of high-tech industrial funds, integrated circuit funds and other industrial funds, introduce and cultivate a number of high-quality enterprises in the industrial chain to land in Beijing, Tianjin and Hebei, and support leading enterprises in the industry to integrate resources and build ecology through mergers and acquisitions. Strengthen the reserve of major manufacturing projects and the planning of scientific research and development and innovation platforms, and actively strive for central financial support. (Responsible units: Municipal Economic and Information Technology Bureau, Municipal Finance Bureau, Municipal Development and Reform Commission, Zhongguancun Management Committee of Municipal Science and Technology Commission, Beijing Economic and Technological Development Zone Management Committee)

　　Fourth, guide the high-end intelligent green development of manufacturing industry

　　(ten) to enhance the independent innovation ability of key links in the industrial chain. Promote the coordinated development of Beijing-Tianjin-Hebei industry, improve the modernization level of industrial chain, accelerate the introduction of the implementation plan of "strengthening the chain to supplement the chain", gather and expand a number of leading enterprises in the industrial chain with leading technology level and strong resource integration ability, and carry out "foundation project" around the basic general technology, key technology and common technology needs to enhance the core competitiveness of manufacturing industry. Vigorously promote the technological transformation of enterprises, support enterprises to carry out intelligent green digital technological transformation against advanced standards, carry out intelligent green development level diagnosis and evaluation around 200 manufacturing enterprises, and accelerate the construction of 20 benchmark intelligent factories in various industries. Support qualified "Xinzhizhao100" projects and green low-carbon projects according to a certain proportion of the total investment, and guide enterprises to improve their innovation ability, production efficiency and green low-carbon development level. (Responsible units: Municipal Economic and Information Technology Bureau, Zhongguancun Management Committee of Municipal Science and Technology Commission, Beijing Economic and Technological Development Zone Management Committee, and district governments)

　　(eleven) to improve the level of opening up the supply of new scenes. Continue to promote the construction of high-level autonomous driving demonstration zone 3.0, deeply practice the networked cloud control technology route, achieve 500 square kilometers coverage, and provide a city-level engineering test platform for the commercialization of intelligent networked automobile application scenarios and the promotion and application of intermediate products. Promote the opening of global smart application scenarios such as transportation, medical care, urban management, and government services, and start the construction of smart city benchmark demonstration zones in urban sub-centers. We will increase the policy support for the application of "the first set", "the first batch" and "the first stream", and support a number of domestic technical products that can be used easily to tackle key problems and enter the chain with the final entry into the supporting supply system of the industrial chain as the standard. Give full play to the function of government procurement policy, and support scientific and technological innovation and the development of small and medium-sized enterprises through measures such as first purchase order and reserved procurement share. (Responsible units: Municipal Economic and Information Technology Bureau, Zhongguancun Management Committee of Municipal Science and Technology Commission, Municipal Finance Bureau, Municipal Development and Reform Commission, Beijing Economic and Technological Development Zone Management Committee, City Sub-center Management Committee, and district governments)

　　(twelve) to speed up the construction of new infrastructure layout. Accelerate the implementation of the special action for the construction of national big data centers, promote the construction of related projects of Beijing-Tianjin-Hebei national data center hub nodes, and make overall arrangements for a number of advanced computing platforms. Promote the integration and application of high-end equipment such as artificial intelligence, new generation information technology such as 5G and robots with the industrial Internet, cultivate more than 20 system solution providers with national influence, and form an industrial Internet empowerment system that serves Beijing-Tianjin-Hebei and radiates the transformation and upgrading of the national industry. Actively promote the landing test of special networks such as the Internet of Vehicles, and comprehensively promote the research, development, verification and application of related technologies. Support key enterprises to build 5G fully connected intelligent unmanned factories, and promote the application of 5G in machine vision inspection, precise remote control and on-site assembly. (Responsible units: Municipal Economic and Information Technology Bureau, Municipal Communications Administration, Zhongguancun Management Committee of Municipal Science and Technology Commission, Municipal Development and Reform Commission, Beijing Economic and Technological Development Zone Management Committee, and district governments)

　　Five, focus on optimizing the development environment of enterprises

　　(thirteen) to strengthen the support of professional and technical skills. We will increase the support for the introduction of technical talents urgently needed by the industry and strengthen the support of supporting policies such as affordable housing. Encourage enterprises to organize multi-level vocational skills training, focus on supporting high-tech enterprises such as intelligent manufacturing, integrated circuits and biomedicine, carry out school-enterprise cooperation and integration of production and education, implement new apprenticeship training for enterprises, implement advanced training programs for specialized technical personnel, and give corresponding training subsidies or financial support according to the training items and scale. Support the head enterprises to establish a master skill studio, give play to the leading role of high-skilled talents in imparting skills, carry out technical research and innovation training for employees in the industry, and give subsidies to the studio project. Strengthen the coordination of services, further optimize and improve the working mechanism, and provide convenience for foreigners and their families to come to China. (Responsible units: Municipal Human Resources and Social Security Bureau, Municipal Bureau of Talents, Municipal Bureau of Economy and Information Technology, Zhongguancun Management Committee of Municipal Science and Technology Commission, Municipal Housing and Urban-Rural Development Committee, Foreign Affairs Office of Municipal Government, Prevention and Control Group for Resumption of Work, Beijing Economic and Technological Development Zone Management Committee, and district governments)

　　(fourteen) to expand consumption to support the sustained recovery of production. Intensify the publicity and promotion of Beijing consumption season activities, and provide financial support for urban commercial complexes and offline retail enterprises above designated size that actively participate in Beijing consumption season activities and meet the requirements. Increase the publicity and promotion of green energy-saving consumption policies, and guide consumers to buy and use green energy-saving goods. We will continue to implement the national subsidy policy for the purchase of new energy vehicles, timely allocate subsidy funds to qualified enterprises, increase the support for the award of charging facilities, study and formulate the price policy of differentiated parking charges for new energy vehicles, and introduce measures to further facilitate the trading of used cars to promote the circulation of used cars. Co-ordinate funds to subsidize the purchase of new energy buses, support the upgrading of cruise taxi fuel vehicles to pure electric vehicles, speed up the research and development of electrification schemes for network vehicles, and introduce preferential access policies for new energy logistics and distribution vehicles. Do a good job in the overall promotion of key products in key areas of this city, strengthen enterprise counseling and supply and demand docking, and further smooth the market access channels for products in this city. (Responsible units: Municipal Bureau of Commerce, Municipal Finance Bureau, Municipal Transportation Commission, Municipal Development and Reform Commission, Municipal Urban Management Commission, Municipal Market Supervision Bureau, Municipal Economic and Information Technology Bureau, Beijing Economic and Technological Development Zone Management Committee, and district governments)

　　VI. Implementing safeguards

　　(fifteen) to establish a guarantee mechanism for the smooth operation of advanced manufacturing industry. Establish an overall coordination mechanism led by the competent city leaders and incorporate it into the working mechanism of the leading group for innovation and development of manufacturing industry in this city. The Municipal Bureau of Economic and Information Technology and the Municipal Development and Reform Commission should continue to strengthen the operation and scheduling of the industrial economy in this Municipality, strengthen the tracking and monitoring of the industrial economic operation situation, accurately grasp the production and operation of key enterprises, strengthen pre-research and pre-judgment, and enrich the policy toolbox. All relevant departments should strengthen their responsibility and take the initiative, formulate detailed implementation rules in a timely manner according to the division of labor, and do a good job in the implementation of tasks with the spirit of "nailing nails". All districts and departments should make full use of and improve the working mechanism of "service package", drive the development of small and medium-sized enterprises in the industrial chain with leading enterprises, listen to the opinions of enterprises in depth, dynamically update the list of service requirements, and solve the pain points and difficulties in the development of enterprises in time; Further guide enterprises to scientifically do a good job in epidemic prevention and control, strengthen the main responsibility of enterprise epidemic prevention and control, ensure the stable operation of key industries, key parks and key enterprises, and provide strong support for the steady growth and high-quality development of the city’s manufacturing industry. The general office of the municipal government shall, jointly with the Municipal Economic and Information Technology Bureau and the Municipal Development and Reform Commission, regularly carry out supervision and evaluation, find problems in time, urge relevant departments and districts to do a good job in rectification and implementation, and get through the "last mile" of policy implementation. Every month, all districts and departments will submit the relevant detailed implementation rules, the coordination and promotion of relevant tasks and the service enterprises to the Municipal Bureau of Economic and Information Technology, the Municipal Development and Reform Commission and send a copy to the general office of the municipal government.

　　Beijing, Nov. 8 (Yao Lu) After the symposium of private enterprises was held, measures to support the development of private economy entered a period of intensive introduction and landing. Recently, the central bank, the Ministry of Industry and Information Technology, the State Administration of Market Supervision, the Ministry of Human Resources and Social Security and other departments have voiced their voices and introduced a series of measures to solve the problems faced by private enterprises and support the development of the private economy.

　　Help turn over the "financing mountain"

　　Recently, some private enterprises have encountered many difficulties and problems in their business development. Some private entrepreneurs described it as "three mountains": the iceberg of the market, the mountain of financing and the volcano of transformation.

　　Especially at present, it is urgent to solve the problem of financing difficulty and expensive financing for private enterprises.

　　In this regard, the symposium of private enterprises proposed that priority should be given to solving the problem that private enterprises, especially small and medium-sized enterprises, are difficult to get financing or even fail to get financing, and at the same time, the financing cost should be gradually reduced.

　　How to help private enterprises cross the "financing mountain"? Yi Gang, governor of the central bank, said that the central bank is making comprehensive measures together with relevant departments, making full use of the "three arrows" from three main financing channels, supporting private enterprises to broaden financing channels and helping them tide over the difficulties.

　　Among them, the "first arrow" is to further expand the pilot scope of private enterprise bond financing support tools to help more private enterprises obtain financing through the bond market; The second arrow is credit support, that is, comprehensive use of monetary and credit policy tools to guide financial institutions to increase credit supply to private enterprises; The "third arrow" is to study the establishment of equity financing support tools for private enterprises to provide phased equity financing support for private enterprises with financial difficulties.

　　Yi Gang said: We have "real money" policies and measures to help private enterprises and small and micro enterprises solve their practical difficulties. The 300-billion-yuan refinancing and rediscounting quota increased by the People’s Bank of China this year is the introduction of a policy and the guidance of "four to two", and it is also necessary to rely on large banks, joint-stock banks and small and medium-sized financial institutions to lend to private enterprises together.

　　The CSRC said that it organized the exchange bond market to launch a pilot of credit protection tools, explored ways to reduce investors’ concerns about buying private enterprise bonds through credit enhancement tools, and supported private enterprise bond financing. The first batch has launched four credit protection contracts for private enterprises, involving three unlisted private enterprises and one listed private enterprise.

　　Miao Wei, Minister of the Ministry of Industry and Information Technology, said that the Ministry of Industry and Information Technology will further play the role of the National SME Development Fund, drive local and social funds to expand the scale of equity financing for small and micro enterprises, and expand direct financing channels for more innovative SMEs. At the same time, promote the study and introduction of administrative regulations to prevent large enterprises from defaulting on small and micro enterprises.

　　Strive to break the "triple door" obstacle

　　Some private enterprises reported that "seeing the policy, you can’t enjoy it; Seeing space, you can’t enter; Seeing the opportunity, we can’t grasp it. Some departments are inefficient in doing things for private enterprises, and there are still barriers such as rolling doors, glass doors and revolving doors.

　　How to break the "triple door" barrier? Zhang Mao, director of the State Administration of Market Supervision, said that we should focus on the goal of building a unified national market, improve the competition policy system, adhere to the principle of competition neutrality, and treat all market players equally. Strengthen competition law enforcement, standardize market order and promote fair competition.

　　For example, deepen the reform of the commercial system and focus on "reducing licenses and pressing licenses" to create a more open, transparent and convenient access environment for private enterprises. Since November 10th this year, the first batch of 106 administrative examination and approval items concerning enterprises have been reformed nationwide. According to the direct cancellation of examination and approval, the examination and approval has been changed to filing, the notification commitment has been implemented, the classified management of access services has been optimized, and the "license reduction after taking photos" has been promoted, so that enterprises can enter both the "gate" of the market and the "small door" of the industry.

　　Miao Wei said that in the next step, the Ministry of Industry and Information Technology will further relax market access and encourage private capital to enter the telecommunications and military industries.

　　Specifically, it includes: First, through the official commercialization of mobile communication resale business, deepen the pilot of broadband access network business, and further guide private capital to enter the basic telecom operation field. The second is to further guide and support private enterprises to participate in the development of integration of defense and civilian technologies.

　　Creating a level playing field has become a major focus of the policy.

　　According to the arrangement put forward by the State Administration of Market Supervision, fair competition review will be fully implemented. Before the end of this year, organize all relevant departments in various regions to complete the self-examination of cleaning up and abolishing the policy documents that hinder the unified market and fair competition, and implement the fair competition review system, and publicize it to the whole society and accept social supervision. At the same time, strengthen anti-monopoly law enforcement. Carry out special rectification actions for public enterprises to restrict competition and monopoly behavior.

　　The Supreme People’s Court said that it is necessary to strengthen the trial of anti-monopoly cases, stop the abuse of monopoly position by market players with dominant market position according to law, and create a unified, open and competitive market environment for the development of private economy.

　　Focus on reducing the burden on enterprises

　　The symposium of private enterprises demanded that the tax burden of enterprises be reduced. We must do a good job in the supply-side structural reform and cost reduction actions, and substantially reduce the burden on enterprises.

　　In terms of specific measures, the Ministry of Human Resources and Social Security said that it is necessary to reduce the nominal rate of social security contributions according to the actual situation, stabilize the payment method, and ensure that the actual burden of social security contributions of enterprises is substantially reduced.

　　The State Administration of Market Supervision said that government services should be optimized to reduce the burden on enterprises and create a healthy and harmonious development environment for private enterprises.

　　Among them, focusing on the fees charged by enterprises, in-depth rectification of illegal price and fee behavior; Carry out special management of intermediary service charges for administrative examination and approval. We will rectify the "red-top intermediary" according to law, and resolutely correct the situation of disguised approval and illegal charges, which will increase the burden on enterprises.

　　In addition, simplify the certification management unit scientifically and reasonably, reduce the types of certification certificates, guide and urge certification institutions to lower the charging standards, and effectively reduce the burden on enterprises. (End)

On the afternoon of June 24th, the College Admissions Committee of Jiangsu Province held a meeting, which reviewed and approved the provincial admission control score line for the first stage of college enrollment in our province in 2021. Subsequently, the Provincial Department of Education held a press conference to inform about the admission control scores of each batch of colleges and universities in our province in the first phase of enrollment this year and the voluntary reporting of the college entrance examination this year.

In the first stage, the provincial admission control scores mainly include special types of admission control lines for subjects such as history and physics, general undergraduate lines, sports undergraduate lines and art undergraduate lines. In order to facilitate the selection of talents in colleges and universities, and at the same time reduce the number of online candidates from the list as much as possible, comprehensive consideration is given to delineating the admission control scores of each batch of provinces.

Specifically, there are 533 points in special types of enrollment history, 501 points in physics and other subjects, 476 points in general undergraduate history and 417 points in physics and other subjects. Physical education undergraduate course history and other subject cultures 366 points/major 110 points, physical education undergraduate course physics and other subject cultures 313 points/major 110 points. Art undergraduate students take a unified examination of subject culture such as art history 335 points/major 170 points, art physics 313 points/major 170 points, music (vocal music, instrumental music) history 310 points/major 145 points, music (vocal music, instrumental music) physics 260 points/major 145 points, and choreographing history 380 points/major.

Approved by the Ministry of Education, some independent undergraduate art colleges (including a few colleges and universities that refer to the implementation of some art undergraduate majors) have their own admission control scores. The scores of provincial admission control for undergraduate examination majors in other colleges and universities are 260 points for history and other subject cultures/qualified majors, and 260 points for physics and other subject cultures/qualified majors. Among them, Obtain music performance, musicology, composition and composition technology theory, pop music, music therapy, radio and television director, fine arts, painting, sculpture, Chinese painting, experimental art, cross-media art, cultural relics protection and restoration, comics, art design, visual communication design, environmental design, product design, clothing and costume design, public art, arts and crafts, digital media art, art and technology, and so on. Candidates who have passed the school examination of packaging design and other majors must also take the corresponding provincial unified examination, and the score of the provincial unified examination of fine arts must reach 160 points, the score of the provincial unified examination of music must reach 120 points, and the score of the provincial unified examination of director must reach 130 points.

After learning the results of college entrance examination, academic level test, admission control scores of each batch, and the number of candidates by segment, candidates will voluntarily fill in online in two stages on the portal website of the Provincial Education Examinations Institute (www.jseea.cn) or a special website (gkzy.jseea.cn).

The first stage is to fill in the professional group volunteers of undergraduate colleges. Among them, the pre-filing is from June 27th to 28th, and the formal filing is from June 29th to July 2nd (the deadline is 17:00 on July 2nd). Including general undergraduate volunteers in advance (including military, public security, politics and law, navigation, local special programs, rural teacher programs, rural order-oriented medical students free training programs, other institutions, etc.), sports undergraduate volunteers in advance, art undergraduate volunteers in advance, and general undergraduate volunteers in advance. In addition, our province has also set up special types of enrollment volunteer columns such as special colleges and universities, comprehensive evaluation (B-type colleges and universities), high-level art troupes and high-level sports teams, for candidates with corresponding qualifications to fill in their volunteers.

In the second stage, fill in the volunteers of professional groups in colleges and universities in batches. Among them, it will be pre-filled from July 25th to 26th and officially filled from July 27th to 28th (the deadline is 17:00 on July 28th). Including general, sports, and art specialties.

After the admission of each batch of parallel volunteer (including traditional (sequential) arts volunteers) is completed, the Provincial Education Examinations Institute will promptly announce the number of professional groups, majors (classes) and plans of colleges and universities that have not completed the enrollment plan. Candidates who have not been admitted will fill in their own online forms for volunteering within the specified time. Please refer to the back of the candidate’s admission ticket for the specific time schedule.

Candidates are required to fill in the volunteers of parallel colleges (including traditional volunteers in art) and solicit volunteers from (parallel colleges) online with their examination number, ID number, password and dynamic password card within the specified time, and be responsible for the accuracy and safety of the information they fill in, without signing on site to confirm the volunteer information.

The Provincial Education Examinations Institute should remind the majority of candidates that this year’s voluntary reporting is divided into two parts: pre-reporting and formal reporting. Candidates who have completed the pre-filling of volunteers can directly import the pre-filling of volunteers into the formal filling system. It is particularly important to note that the pre-filled volunteers do not take effect, and only the officially filled volunteers are the basis for admission.

The admission time has also been determined. General admission time: July 8-14, the Japanese department will be admitted to colleges and universities in advance; July 17-25, admitted to Japanese universities; College admission from August 1st to 8th. Admission time for sports and art classes: July 8-16, Japanese classes are admitted to colleges and universities in advance (among which art classes are divided into 3 small batches); College admission from July 29th to 31st.

Linking > > >

What are the special types of enrollment?

The "special type enrollment" in Jiangsu college entrance examination refers to the enrollment projects with strong foundation plan, comprehensive evaluation, college special projects, local special projects, high-level art troupe, military academy enrollment and other special requirements.

According to the enrollment regulations of the Ministry of Education, the provinces that implement the comprehensive reform of college entrance examination and merge undergraduate batches must draw special enrollment control scores with reference to the proportion of enrollment plans of liberal arts and sciences in previous years. The "Opinions on Enrollment of Ordinary Colleges and Universities in Jiangsu Province in 2021" clearly stipulates that special types of enrollment control scores are divided according to the general category (history and other subjects) and the general category (physics and other subjects), with reference to the proportion of enrollment plans of the liberal arts and sciences in previous years.

The statistics of college entrance examination in our province are released one by one

On the 24th, the Provincial Education Examinations Institute announced the statistical table of the general college entrance examination in Jiangsu Province in 2021.

According to the statistics, there are 101 people with a score of 632 or above in the general category (history and other subjects), 1,651 people with a score of 600 or above, 10,193 people with a score of 562 or above, and 55,510 people with a score of 476 or above. There are 101 general subjects (such as physics) with a score of 661 or above, 1049 with a score of 636 or above, 10015 with a score of 595 or above, 86521 with a score of 500 or above, and 150598 with a score of 417 or above.

Piecewise statistics can let candidates know their grades, which is one of the important reference bases for candidates to fill in their volunteers. Experts in gaozhao remind candidates that before they fill in their volunteers, they must consult the enrollment policy of our province and the relevant contents of the special issue of the plan compiled by the Provincial Education Examinations Institute, carefully read the important materials in the special issue of the plan, such as Notes on Candidates’ Filling in Volunteers, Notes on parallel volunteer’s Filing, and the enrollment regulations of relevant colleges and universities, watch the guidance film on volunteering in the college entrance examination, and according to the requirements of the selected subjects of the subjects, professional groups and majors, as well as the candidates’ own college entrance examination scores and scores. Candidates should also be reasonably positioned, and should know their ranking according to their own achievements through subsection statistics.

Summer is coming, and a large number of fruits are on the market. Many office workers like to buy more at one time on weekends, keep them in the refrigerator, and take them out when they want to eat, which makes them feel cold. However, not all fruits are suitable to be stored in the refrigerator, and some fruits are naturally "cold-afraid". Putting them in the refrigerator will not only freeze the fruits, but also destroy their quality and flavor.

In general, the daily preservation of fruits can be divided into the following four categories:

1, can’t put it in the refrigerator, otherwise it will be frostbitten. Such as bananas, carambola, loquat and so on.

2. It can be put in the refrigerator, but it must be ripened first (that is, the unripe fruit cannot be put in the refrigerator). Such as durian, Sakyamuni, passion fruit, persimmon, etc.

3, it must be put into the refrigerator to last for a long time. Such as: peach, mulberry, plum, litchi, longan, rambutan, cherry, chestnut, guava, grape, pear, strawberry, mangosteen, pitaya, melon, grapefruit and so on.

4. It can be stored at room temperature or refrigerated in refrigerator. Such as: lemon, pineapple, grape, orange, olive, jujube, apple, watermelon, orange, coconut, grapefruit, sugarcane and so on.

There is a knack for storing fruit.

Because of different kinds of fruits, the optimum storage temperature is also different.

watermelon

Watermelon is stored at 10-12 degrees Celsius, and chilling injury will occur when the temperature is lower than 9.5 degrees Celsius.

Watermelons that have not been cut can be stored for more than 10 days at room temperature. Pay attention to placing watermelons in a cool, ventilated and dry place suitable for watermelon storage. If you want to eat some cold taste, you can put the watermelon in the refrigerator for two hours before eating, and the flavor is the best.

Watermelon itself has a high content of water and fermented sugar, which is easy to breed bacteria. After watermelon is cut, the internal fermented sugar is in direct contact with the outside world, which is easy to breed bacteria. Therefore, after watermelon is cut, it must be stored in the refrigerator, but it can only be stored for 12 to 24 hours at most.

mango

The best storage temperature of mango is about 10℃-13℃, and the peel will turn black when the temperature is lower than 8℃.

Therefore, it is best to store mango in a dark and cool place. If it must be placed in the refrigerator, it should be placed in a vegetable and fruit tank with higher temperature, and the storage time should not exceed two days.

banana

Bananas are most suitable for storage at 8℃-23℃. High temperature will easily lead to over-ripening and blackening, while temperature below 5℃ will easily lead to frostbite and blackening.

You can wash the bunches of bananas you bought with clean water, wipe the water with a clean cloth, put the bananas in a plastic bag, put an apple in it, exhaust the air from the bag as much as possible, tie the bag tightly, and put it in a ventilated and cool place at home.

grape

As soon as many people buy grapes home, they are used to washing them immediately and putting them in the refrigerator, which is very undesirable.

It’s best to wait until the grapes are ready to be eaten before washing them. It’s easy to go bad after washing and storing them.

The correct way is to sort out the bad grains and sundries in the grapes, then cut them off one by one and put them in a fresh-keeping box, but keep the pedicel and don’t expose the pulp to the air, otherwise it will not only attract insects, but also accelerate oxidation. After that, absorb the water with paper, seal it with plastic wrap and put it in the constant temperature room of the refrigerator.

mangosteen

Mangosteen is easy to deteriorate. If you want to keep it for a long time, you must ensure low temperature and less oxygen.

In general, tropical fruits can’t be stored in the refrigerator, but mangosteen is different. Because low temperature can reduce the loss of water in mangosteen, reduce the activity of pectinase and delay aging, mangosteen should be stored in refrigerator.

pawpaw

Mature papaya pulp is very soft and difficult to preserve, so you should eat it immediately after buying it back.

If you don’t intend to eat it immediately after buying it, it is recommended to choose papaya that is not completely yellow and slightly blue. It will be left for 1 to 2 days after you get home, and then wrapped in a fresh-keeping bag and put in the refrigerator for refrigeration. It can be kept for about 4 to 5 days at most. The optimum storage temperature of papaya is about 7℃.

Three points for attention when eating iced fruits.

(1) Note 1:

Eating time is particular. Try not to eat chilled fruit when you are just full or on an empty stomach. You can eat it after 1~2 hours after meals.

(2) Note 2:

It is advisable not to eat too much each time, so as not to cause gastrointestinal discomfort. For example, don’t eat more than 500 grams of watermelon at a time, about 15 grapes, no more than 1 peach and 10 ~ 15 strawberries.

(3) Note 3:

If the watermelon is not eaten at one time, the surface should be cut off before eating it next time, and other fruits stored in the refrigerator should be washed again before eating.

　　[car home Industry] In two weeks, the automatic transmission industry in China will usher in a major event. Point the coordinates to Yangzhong, Jiangsu, and Hive Yichuang Industrial Park. The first 9DCT automatic gearbox and hybrid powertrain independently developed by local enterprises in China will be officially launched. This indicates that Honeycomb Yichuang "I Era 2.0" will realize industrialization.

　　As the core of Great Wall Motor’s power system, Honeycomb Yichuang’s "I Era" new generation powertrain 4N20 engine and 9DCT/9HDCT automatic gearbox are both mass-produced in Yangzhong Industrial Park. At the same time, Honeycomb Yichuang’s first 3.0L V6 gasoline engine HY6Z30 and the first 9AT/9HAT are also under simultaneous mass production planning. Recently, Zheng Lipeng, vice president of Honeycomb Yichuang, revealed more key information to car home.

　　Many people may be unfamiliar with hives. Honeycomb Yichuang, cultivated by Great Wall Motor for many years, is one of the cores of its supply chain system.

　　In 2018, Great Wall Motor reorganized its parts system, integrating Honeycomb Yichuang (engine, gearbox, electric drive, intelligent steering), Noble Automobile (seat, interior and exterior decoration, rubber, etc.), Jingcheng Engineering (chassis, die casting, equipment, etc.) and Mande Electronics (photoelectric, thermal system, electrification business) successively, participating in market competition and supplying to the outside world. In addition, the power battery industry operates independently with honeycomb energy, and the hydrogen energy industry operates independently with untapped energy and combustion power.

"Honeycomb Easy Creation mainly includes power, transmission, electric drive and intelligent steering business"

　　At present, Honeycomb Easy Creation is mainly located in Baoding, Xu Shui, Tianjin, Yangzhong, Chongqing and Taizhou. In Yangzhong, the project of honeycomb power system, transmission system and electric drive system will be put into production before the end of this year, and the die-casting project of intelligent steering system and Jingcheng Engineering will be completed by the end of this year.

■ The supply system is completely localized.

　　Many years ago, when Great Wall Motor no longer relied on foreign procurement of engines, the automatic gearbox became its breakthrough point, and it did not hesitate to point to 7DCT. Since mass production in 2017, with the huge market of Great Wall Motor, Honeycomb Yichuang 7DCT has become a well-known product, and the market share will exceed 2 million units by the end of this year.

　　Soon, not only the Great Wall, but also many local enterprises in China will enter the 9th gear era.

　　In July this year, the 4N20 engine in the new generation powertrain of the "I Era" was rolled off the assembly line in Honeycomb Yangzhong, and 9DCT and 9HDCT will be put into production in November, followed by DHT dual-motor hybrid special gearbox. In the future, with the completion of new factories in Taizhou, Jiangsu and Yongchuan, Chongqing, Honeycomb Yichuang will establish a perfect gearbox production system throughout the country.

　　Why do you want to do the ninth gear? The purpose is to make the engine more efficient. On the one hand, the efficient range of Honeycomb’s innovative first-generation engine will be wider, and on the other hand, the engine will operate in the efficient area as much as possible through the cooperation of the 9-speed automatic gearbox. In addition to the horizontal 9DCT, Honeycomb Yichuang China’s first vertical 9AT and hybrid system will also be unveiled in the future.

　　Now, the hive can completely not rely on imported parts, the gearbox supply chain is completely localized, and the upstream suppliers are also local and foreign (required to build factories in China). Each component will have different suppliers and can be substituted for each other to maintain the stability of the supply system.

　　The engine and automatic gearbox are only part of the layout of the honeycomb enterprise.

　　In terms of electric drive, Honeycomb is supplied by Euler. Since it was put into production in June, the market has more than 10,000 units, and the flat wire motors at the forefront of the market have already been laid out. The Honeycomb Motor Project Team (the predecessor of Honeycomb Electric Drive) made it clear at the beginning of its establishment in 2012 that flat wire is the future development trend, and in 2015, the first Hairpin drive motor was trial-produced. In Yangzhong, the future production capacity of Hairpin motors will be expanded to 500,000 units/year. At present, honeycomb electric drive has developed 45kW-150kW products, while 200kW products are under development.

　　In terms of steering, Honeycomb turned to independently develop DP-EPS intelligent steering system, which was applied to the latest (|) and Great Wall H9. In the future, Yangzhong will also invest 250,000 sets of annual steering system capacity. Honeycomb turning will also realize foreign matching.

■ Mastering core technologies and opening up cooperation.

　　Undeniably, the supply system of Great Wall Motor has realized "internal circulation" in China. Zheng Lipeng said: "If we really want to have core competitiveness, we must achieve comprehensive control from hardware manufacturing to software design."

　　In Taizhou, the dual clutch module and hydraulic module will be produced independently, which means that all the core components of the automatic gearbox can be controlled by the hive. At the same time, the control software of automatic gearbox is also owned by Honeycomb, and the engine control software will also be independently developed by the end of next year.

　　It is worth noting that turbocharger, transfer case, hydrogen fuel cell air compressor, 70Mpa hydrogen storage bottle, valve body and honeycomb are also laid out, and some production lines are under construction. These are areas that were once monopolized by foreign companies in the past.

　　"When we have the ability to produce key components such as dual clutch modules and hydraulic modules, it does not mean that we will weaken cooperation with companies such as Borgwarner and Schaeffler, which are still the most important partners of the hive." Zheng Lipeng emphasized that the ability of self-production can convince the partners that the hive has mastered many patents in these key areas.

"Gun 2020 2.0T Travel Edition"

　　In Zheng Lipeng’s view, "when others get your new technology and design, they are mostly skeptical, but if we can verify and produce, it will not be like this." It is reported that according to the feedback from users of Great Wall H9 and Gun, it is hoped that the next generation of transfer gears can shift gears dynamically and their performance will be further improved. To this end, the Great Wall has put forward a brand-new design and is talking with suppliers about how to produce it.

　　All kinds of new ideas are based on the demand of product differentiation. Looking back many years ago, China enterprises such as Great Wall were still very weak, and they had no right to speak when talking about cooperation with top suppliers in the world. It was good that the other side was willing to cooperate and provide products. Now, when the procurement demand of the Great Wall is large enough and the market is rich enough, a new concept of positive research and development will be needed to build a competitive advantage.

　　"We don’t have to do everything ourselves. The actual application is external suppliers plus some self-production. The purpose of self-production of key components is to master core technical capabilities and cultivate local supply chains. " Zheng Lipeng said, "We have basically achieved 100% localization of all products."

　　It is expected that the honeycomb enterprises will start to support local enterprises with their own core technologies.

　　In fact, Honeycomb Yichuang has been looking for opportunities for foreign breakthroughs since it confirmed its independence from the Great Wall in 2018. In August 2019, BAIC, Great Wall and SDIC China Merchants (the management company of SDIC Innovation and the second largest shareholder of Honeycomb Energy) signed a strategic cooperation agreement. Since then, BAIC and Honeycomb Yichuang have become closer and closer. In May this year, the new Beijing BJ40 was launched with HY4C20B 2.0T gasoline engine produced by Honeycomb Yichuang. This is the cooperation between two China brand car companies, BAIC and Great Wall, and it is also the result of Honeycomb’s active external support.

"Beijing BJ40 2020 2.0T automatic four-wheel drive urban hunter edition"

　　Before the end of next year, in addition to BAIC, Honeycomb Yichuang will also add four engine customers and two gearbox customers, and the development work is currently underway. In addition, the new customer cooperation information of motors and batteries will be released one after another, and the hybrid special transmission DHT will also support some new forces to build cars in the future.

■ cut in from mixing to create an ecological circle

　　Not long ago, the "Technology Roadmap 2.0 for Energy-saving and New Energy Vehicles" just officially released has been very clear. It is planned that by 2035, the proportion of energy-saving vehicles and new energy vehicles in China will each account for about 50%. This means that the policy orientation confirms the important strategic position of energy-saving hybrid vehicles.

　　At present, the choice of hybrid technology route is not the same in the major automobile markets around the world. In China, the application of P2 and DHT architecture is more prominent. From the perspective of consumer demand, in addition to energy saving and consumption reduction, different consumer groups show diversity in cost performance, power and extreme demand, and the research and development innovation of hybrid technology requires multiple design concepts.

"Honeycomb Easy-to-Create Hybrid System Solution"

　　According to the data, Honeycomb Yichuang has created a hybrid product design concept of power system called "X in One". Where "X" stands for diversified product R&D platform, "in" stands for diversified integration of power system, and "One" stands for flexible product service oriented to customer demand.

　　Zheng Lipeng said that such a platform combination can meet the needs of different user groups.

　　At present, Honeycomb has built 2.0T and 3.0T hybrid engines. Matching 9HDCT and DHT hybrid transmission in transverse structure, matching with 1-speed or 2-speed eAD electric drive axle, can match the honeycomb energy lithium-ion battery (PHEV); Under the vertical structure, it is matched with the 9HAT and DHT hybrid special transmission, and the first gear TOD2 is a high-performance transfer gear for TOD, which can match the lithium ion battery (PHEV).

　　In the longer term, platformization is just the beginning. In the future, based on the platform and resource advantages within the Great Wall Holding System, Honeycomb Yichuang will strive to build a full-spectrum automotive powertrain technology ecology covering traditional-hybrid-pure electric-hydrogen fuel power. Honeycomb Yichuang will cooperate with Honeycomb Energy and Unprovoked Energy to build a full-spectrum business ecosystem of future automobile power system around the future automobile power system.

　　By 2025, Honeycomb will achieve an engine capacity of 1.95 million units, a gearbox capacity of 2 million units, an electric motor drive capacity of 550,000 units and a power battery capacity of 100GWh h..

Editor’s summary:

　　In recent years, it is a trend that the excellent parts enterprises cultivated by the automobile factory are gradually independent, but it is not easy to really get rid of the backer to achieve external supply. Honeycomb Easy Creation, Honeycomb Energy, Unprotected Energy, and three other independent parts enterprises cultivated by the Great Wall are all worthy of in-depth study.

　　The breakthrough of honeycomb enterprises began with engines and automatic gearboxes, and strengthened the route of hybrid, pure electric and hydrogen energy. Nowadays, Honeycomb is easy to create, including Honeycomb Energy and Unprotected Energy. The total number of employees in the world has reached 18,000. Team management may be a relatively difficult problem for Honeycomb. In fact, Wei Jianjun, the chairman of Great Wall Motor, has been promoting the reform, and Honeycomb is also following up the establishment of combat units and mechanisms, and implementing the concept of coordinated operations. In Zheng Lipeng’s eyes, the Great Wall provides a very clean platform for the right people to do the right things, without any professional background. As long as you have the ability and can respond quickly, you will have a chance to rise. (Text/car home Liu Honglong)